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Abstract 
Urinary tract infections (UTIs) remain the common infections diagnosed in 
outpatients as well as hospitalized patients. A major concern to the medical 
community is the increasing occurrence of multi-drug resistant (MDR) E. coli, 
presenting challenges to the empirical treatment of UTI. Therefore, current knowledge 
on antimicrobial susceptibility pattern is essential for appropriate therapy. ESBL 
producing bacteria may not be detectable by routine disk diffusion susceptibility test, 
leading to inappropriate use of antibiotics and treatment failure. The aim of this study 
was to determine the distribution and antibiotic susceptibility patterns of bacterial 
strains isolated from patients with community acquired urinary tract infections (UTIs) 
at Aligarh hospital in India as well as identification of ESBL producers in the 
population of E. coli and Klebsiella spp. isolates. Urinary isolates from symptomatic 
UTI cases attending to the J.N. Medical College and hospital at Aligarh were 
identified by conventional methods. Antimicrobial susceptibility testing was done by 
Kirby Bauer's disc diffusion method. Isolates resistant to third generation 
cephalosporin were tested for ESBL production by double disk synergy test method. 
Of the 920 tested samples, 100 samples showed growth of pathogens among which the 
most prevalent were E. coli (61%) followed by Klebsiella sp (22%). The majority 
(66.66%) of the isolates were from women while the remaining were from men. 
Among the gram-negative enteric bacilli high prevalence of resistance was observed 
against ampicillin and co-trimoxazole. Most of the isolates were resistant to 4 or more 
number of antibiotics. 42% of isolates were detected to produce ESBL among which 
34.42 % were E. coli isolates. This study revealed that E. coli was the predominant 
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bacterial pathogen of community acquired UTIs in Aligarh, India. This study also 
demonstrated an increasing resistance to ampicillin and Co-trimoxazole and 
production of extended spectrum P-lactamase among UTI pathogens in the 
community. 
India is not excluded from the problems encountered world-wide in the 
treatment of community acquired urinary tract infections, commonly caused by 
different members of family Enterobacteriaceae. These pathogenic bacteria produces 
enzymes that include the B-lactamases and extended-spectrum B-lactamases (ESBLs) 
capable of hydrolysing the B-lactam antibiotics and in particular the expanded-
spectrum cephalosporins which are frequently used. These bacteria are often multiple 
resistant. Transmission of these bacterial strains between patients is a serious problem 
in community settings. Antimicrobial resistance genes are often clustered in integrons, 
genetic elements capable of recombination, which are responsible for the spread of 
varied resistant markers in the community. 
We have also determined the prevalence of integrons among ESBLs producing 
Escherichia coli causing community acquired urinary tract infections (UTIs). All 
ESBLs producing E. coli isolates were tested for integrons by amplifying 5'CS and 
3'CS region, the class of integrons was fiirther confirmed by specifically amplifying 
Int land Sull genes. Of the twenty two isolates tested, seven were found to have class 
1 integrons. DNA sequencing of these isolates showed the presence of multiple gene 
cassettes i.e. aadAl, aadA5, dfr7, dfrl7, aacA4, and CmlAl. This study demonstrated 
that class 1 integrons are widely prevalent in Indian isolates and hence they might play 
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a role in multiple drug resistance in E. coli of community acquired urinary tract 
infections. 
We also examined the role of B-lactamases in resistance development in 
commonly encountered pathogens implicated in urinary tract infections. Resistance to 
the 6-lactam agents, ceftriaxone, ceftazidime, cefotaxime, cefoxitin and penicillins 
was suspected to involve the presence of one or more P-lactamases in the isolates from 
patients attending OPD at J.N.M.C. hospital. 34% of all the E. coli isolates were found 
positive for ESBLs production. These P-lactamase producers were characterized by 
genetic analysis (DNA amplification by PCR) to investigate the presence of possible 
genes responsible for resistance development. B-lactam resistance could be attributed 
to the presence and action of B-lactamases such as the TEM, SHV and CTX-M type 
enzymes. The most common group of ESBLs not belonging to the bla TEM or bla SHV 
families were termed bla CTX-M- The designation "CTX-M" refers to potent activity 
against cefotaxime, an aminotiazolil cephalosporin with a methoximino group; these 
enzymes have only remnant activity toward ceftazidime, another aminotiazolil 
cephalosporin with a 2-carboxy-2-oxypropaneimino group instead of the methoximino 
group. These enzymes are inhibited by clavulanic acid, sulbactam and tazobactam. 
There are only few reports available on prevalence of CTX-M beta-lactamases in 
some parts of India. Therefore we determined the prevalence of these enzymes in our 
region by using PCR. Among all isolates, only three isolates were found to be positive 
for presence of CTX-M gene. As reported earlier by many groups that bla CTX-M 
enzymes were plasmid mediated, in our study we found that all three isolates harbor 
bla CTX-M genes on chromosomal DNA. This is first report from India showing the 
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presence of bla CTX-M gene on bacterial chromosome. Nucleotide sequence analysis of 
these PCR products revealed that all the three amplicons belong to CTX-15 type beta-
lactamases. 
To evaluate the role of plasmids in spread of drug resistance we carried the 
conjugation experiments. We found that eighteen of the twenty two strains showed 
transfer of multiple resistance markers from donor to recipient susceptible strain EJ-
53. Transfer frequency of these resistance markers varied between 3A7^\0'^ and 
5.2x10". We further investigate the genotypes of the twenty two ESBLs producing E. 
coli strains by PFGE. Pulsed-field gel electrophoresis (PFGE) of Xbal digests was 
performed to determine the genetic similarity amongst isolates showing multidrug 
resistance. The isolates investigated were genotypically diverse and divided in various 
types and subtypes by applying criteria of Tenover. 
It is quite alarming to note that almost all of the isolates included in this study 
were found resistant to four or more antibiotics. This study concludes that E. coli and 
other isolates were more sensitive to imipenem and amikacin compared to the other 
antibiotics tested and therefore these may be the drugs of choice for the treatment of 
community-acquired UTIs in our region. This study also shows that the integrons are 
one of the means of antibiotic resistant marker transfer among members of 
Enterobacteriaceae. Our findings unveil the increasing role of the bla-crx-M B-
lactamases in antibiotic resistance and emphasize on the significance of appropriate 
empirical treatment for infections caused by coliforms, especially in urinary tract 
infection patients. This study also shows that the horizontal gene transfer of 
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antimicrobial resistance genes can occur very efficiently and at a high rate among 
Enterobacteraceae in a community setting. 
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Abstract 
Urinary tract infections (UTIs) remain the common infections diagnosed in 
outpatients as well as hospitalized patients. A major concern to the medical 
community is the increasing occurrence of multi-drug resistant (MDR) E. coli, 
presenting challenges to the empirical treatment of UTI. Therefore, current knowledge 
on antimicrobial susceptibility pattern is essential for appropriate therapy. ESBL 
producing bacteria may not be detectable by routine disk diffusion susceptibility test, 
leading to inappropriate use of antibiotics and treatment failure. The aim of this study 
was to determine the distribution and antibiotic susceptibility patterns of bacterial 
strains isolated from patients with community acquired urinary tract infections (UTIs) 
at Aligarh hospital in India as well as identification of ESBL producers in the 
population of E. coli and Klebsiella spp. isolates. Urinary isolates from symptomatic 
UTI cases attending to the J.N. Medical College and hospital at Aligarh were 
identified by conventional methods. Antimicrobial susceptibility testing was done by 
Kirby Bauer's disc diffusion method. Isolates resistant to third generation 
cephalosporin were tested for ESBL production by double disk synergy test method. 
Of the 920 tested samples, 100 samples showed growth of pathogens among which the 
most prevalent were E. coli (61%) followed by Klebsiella sp (22%). The majority 
(66.66%) of the isolates were from women while the remaining were from men. 
Among the gram-negative enteric bacilli high prevalence of resistance was observed 
against ampicillin and co-trimoxazole. Most of the isolates were resistant to 4 or more 
number of antibiotics. 42% of isolates were detected to produce ESBL among which 
34.42 % were E. coli isolates. This study revealed that E. coli was the predominant 
XI 
tibstraet 
bacterial pathogen of community acquired UTIs in Aligarh, India. This study also 
demonstrated an increasing resistance to ampicillin and Co-trimoxazole and 
production of extended spectrum p-lactamase among UTI pathogens in the 
community. 
India is not excluded from the problems encountered world-wide in the 
treatment of community acquired urinary tract infections, commonly caused by 
different members of family Enterobacteriaceae. These pathogenic bacteria produces 
enzymes that include the B-lactamases and extended-spectrum B-lactamases (ESBLs) 
capable of hydrolysing the B-lactam antibiotics and in particular the expanded-
spectrum cephalosporins which are frequently used. These bacteria are often multiple 
resistant. Transmission of these bacterial strains between patients is a serious problem 
in community settings. Antimicrobial resistance genes are often clustered in integrons, 
genetic elements capable of recombination, which are responsible for the spread of 
varied resistant markers in the community. 
We have also determined the prevalence of integrons among ESBLs producing 
Escherichia coli causing community acquired urinary tract infections (UTIs). All 
ESBLs producing E. coli isolates were tested for integrons by amplifying 5'CS and 
3'CS region, the class of integrons was fiirther confirmed by specifically amplifying 
Int land Sull genes. Of the twenty two isolates tested, seven were found to have class 
1 integrons. DNA sequencing of these isolates showed the presence of multiple gene 
cassettes i.e. aadAl, aadA5, dfr7, dfrl7, aacA4, and CmlAl. This study demonstrated 
that class 1 integrons are widely prevalent in Indian isolates and hence they might play 
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a role in multiple drug resistance in E. coli of community acquired urinary tract 
infections. 
We also examined the role of 6-lactamases in resistance development in 
commonly encountered pathogens implicated in urinary tract infections. Resistance to 
the B-lactam agents, ceftriaxone, ceftazidime, cefotaxime, cefoxitin and penicillins 
was suspected to involve the presence of one or more p-lactamases in the isolates from 
patients attending OPD at J.N.M.C. hospital. 34% of all the E. coli isolates were found 
positive for ESBLs production. These P-lactamase producers were characterized by 
genetic analysis (DNA amplification by PCR) to investigate the presence of possible 
genes responsible for resistance development. B-lactam resistance could be attributed 
to the presence and action of B-lactamases such as the TEM, SHV and CTX-M type 
enzymes. The most common group of ESBLs not belonging to the bla TEM or bla SHV 
families were termed bla CTX-M- The designation "CTX-M" refers to potent activity 
against cefotaxime, an aminotiazolil cephalosporin with a methoximino group; these 
enzymes have only remnant activity toward ceftazidime, another aminotiazolil 
cephalosporin with a 2-carboxy-2-oxypropaneimino group instead of the methoximino 
group. These enzymes are inhibited by clavulanic acid, sulbactam and tazobactam. 
There are only few reports available on prevalence of CTX-M beta-lactamases in 
some parts of India. Therefore we determined the prevalence of these enzymes in our 
region by using PCR. Among all isolates, only three isolates were found to be positive 
for presence of CTX-M gene. As reported earlier by many groups that bla CTX-M 
enzymes were plasmid mediated, in our study we found that all three isolates harbor 
bla cTx-M genes on chromosomal DNA. This is first report from India showing the 
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presence of bla CTX-M gene on bacterial chromosome. Nucleotide sequence analysis of 
these PCR products revealed that all the three amplicons belong to CTX-15 type beta-
lactamases. 
To evaluate the role of plasmids in spread of drug resistance we carried the 
conjugation experiments. We found that eighteen of the twenty two strains showed 
transfer of multiple resistance markers from donor to recipient susceptible strain EJ-
53. Transfer frequency of these resistance markers varied between 3.17x10"^ and 
5.2x10''. We further investigate the genotypes of the twenty two ESBLs producing E. 
coli strains by PFGE. Pulsed-field gel electrophoresis (PFGE) of Xbal digests was 
performed to determine the genetic similarity amongst isolates showing multidrug 
resistance. The isolates investigated were genotypically diverse and divided in various 
types and subtypes by applying criteria of Tenover. 
It is quite alarming to note that almost all of the isolates included in this study 
were found resistant to four or more antibiotics. This study concludes that E. coli and 
other isolates were more sensitive to imipenem and amikacin compared to the other 
antibiotics tested and therefore these may be the drugs of choice for the treatment of 
community-acquired UTIs in our region. This study also shows that the integrons are 
one of the means of antibiotic resistant marker transfer among members of 
Enterobacteriaceae. Our findings unveil the increasing role of the bla-cix-M 6-
lactamases in antibiotic resistance and emphasize on the significance of appropriate 
empirical treatment for infections caused by coliforms, especially in urinary tract 
infection patients. This study also shows that the horizontal gene transfer of 
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antimicrobial resistance genes can occur very efficiently and at a high rate among 
Enterobacteraceae in a community setting. 
XV 
j^eview 
of 
Literature 
Chaptizr-! 
1.1 Introduction 
Escherichia coli is a very diverse species of bacteria found naturally in the 
intestinal tract of all humans and many other animal species. A subset of E. coli are 
capable of causing enteric/diarrhoeal disease, and Escherichia coli strains capable of 
causing disease outside the gastrointestinal tract belong to a diverse group of isolates 
referred to as extra intestinal pathogenic E. coli (ExPEC) [Russo et al., 2000; Johnson 
et al., 2005]. ExPEC strains are responsible for a variety of diseases, including urinary 
tract infections (UTIs), newborn meningitis, septicemia, nosocomial pneumonia, intra-
abdominal infections, osteomyelitis and wound infections [Eisenstein et al., 1988; de 
Louvois et al., 1994; Russo et al., 2000; Johnson et al., 2002]. Uropathogenic E. coli 
(UPEC), a prominent member of the ExPEC family, is responsible for up to 90% of 
uncomplicated UTIs in otherwise healthy individuals [Zhang et al., 2003]. 
1.2 Urinary Tract Infections (UTIs) 
Urinary tract infections (UTIs) are among the most common human bacterial 
infections, with global infection rates nearing 180 million per year [Russo & Johnson, 
2003]. UTIs are clinically defined as the bacterial colonization of any tissue along the 
urinary tract, from the urethral opening to the kidneys. The term urinary tract infection 
encompasses a broad range of clinical entities that are associated with a common 
finding of a significant amount of bacteria in urine and a positive urine culture [Duse 
& Klugman, 1993]. The infection may be community acquired or nosocomial, often as 
a consequence of urethral catheterization and is more prevalent in women [Neu, 1992; 
Begg & Gillespie, 2000; Bannister, Hooton, 2001]. 
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1.2.1 Aetiology of UTIs 
Enterobacteriaceae are endogenous to the gastrointestinal tract and are often 
implicated in ± 80% of all UTIs. In Figure 1.1 it can be seen that Escherichia coli 
causes 50% - 80% of cystitis cases and community acquired UTIs [Finkelstein et al., 
1998; Sanders et al., 1988] while Klebsiella pneumoniae is responsible for another 8% 
to 13%. Staphylococcus saprophyticus cause between 5% and 20% [Neu, 1997] and 
together with group D Streptococci (Enterococci) are the only Gram positive enteric 
bacteria that commonly cause UTIs [Rebuck et al., 2000]. Infrequent causative agents 
of UTIs include bacteria such as Staphylococcus aureus, Gardnerella vaginalis, 
Corynebacterium and Lactobacilli, yeasts such as Candida ( in diabetics or patients 
with indwelling urinary catheters) and viruses such as Adenovirus type 2 (associated 
with acute haemorraghic cystitis in children) [Duse & Klugman, 1993]. Non-specific 
urethritis is frequently caused by sepsis of Chlamydia ureaplasma and Mycoplasma, 
mainly introduced by sexual contact. Gonococci may also invade the urinary tract as 
well as the reproductive system, by entering the bladder via the urethra with an interim 
phase or periurethral and distal urethral colonization [Hooton, 2000]. 
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OUTPATIENTS 
Escherichia coli HI Coagulase-negative staphylococci 
Proteus mirabilis H Other Gram-positives H Other Gram-negatives 
Figure 1.1 Common causes of urinary tract infections. The percentage of infections 
caused by different bacteria in outpatients is shown. Escherichia coli is by far the most 
common isolate in both groups of patients. (Taken from Medical Microbiology by 
Mims, Playfair, Roitt, Wakelin and WUliams; 1998) 
- 3 - 5.^ --' 
Chaptizr-1 
1.2.2 Clinical manifestations of UTIs 
Infections of the lower urinary tract may be confined to the urethra (urethritis) or 
the bladder (cystitis), with symptoms including frequent, painful, and urgent urination. 
Diagnosis is typically made based upon pyuria of at least 10 leukocytes per high 
power microscopic field and the presence of at least 10^  colony forming units of 
infecting organisms per mL of clean catch urine, though infections with lower 
numbers of organisms are not infrequent. Upper tract infections frequently occur in the 
kidneys (pyelonephritis), often accompanied by flank pain and tenderness, fever, 
chills, nausea, and vomiting and may also include symptoms of lower UTI [Sobel & 
Kaye, 2004]. Many urinary infections can, however, occur without specific symptoms 
[Sanders et al., 1988]. Based on the presence of physiological or anatomical 
abnormalities, including obstruction of the bladder outlet, vesicoureteral reflux, 
enlarged prostate in men, diabetes and pregnancy, UTIs are referred to as complicated, 
whereas those in an uncompromised host are termed uncomplicated [Kunin, 1987; 
Sobel & Kaye, 2004]. 
1.2.3 Microbiological causes of UTIs 
There are several organisms known to cause UTIs, including Pseudomonas 
aeruginosa. Staphylococcus saprophyticus, Enterococcus spp., Proteus mirabilis, 
Klebsiella spp., Citrobacter spp., and most importantly Escherichia coli, the most 
common infecting agent [Nicolle, 2002; Zhanel et al., 2005]. E. coli is an enteric 
Gram-negative bacillus found in the large intestine of all healthy individuals, and is 
responsible for 70-95% of episodes of cystitis and more than 90% of cases of 
pyelonephritis [Hooton, 2003; Russo & Johnson, 2003]. Certain serogroups of £. coli, 
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based on their ability to adhere to and colonize the urinary tract, are known as 
uropathogenic E. coli (UPEC). UPEC are distinguished from commensals by the 
presence of special virulence factors, including adhesins and toxins, which enhance 
their ability to both cause infection and evade host responses. Adhesins are 
chromosomally encoded, non-filamentous outer-membrane proteins known as pili or 
fimbriae [Sobel & Kaye, 2004]. UPEC express many types of fimbriae differentiated 
by their receptor affinity. Type-1 fimbriae, characterized by their ability to bind 
mannose-containing oligosaccharides on host glycoproteins, are encoded by the fim 
gene cluster, composed of nine genes [Emody, 2000]. These are especially well known 
as important factors for colonization of the bladder. The FimH adhesin, located on the 
tip of the pilus, recognizes terminal D-mannose moieties on secreted and cell-bound 
glycoproteins and is responsible for UPEC cell binding to host cells [Bergan, 1997]. 
Single nucleotide differences in the fimH gene produce FimH proteins with the UTI-
associated mono-mannose binding phenotype as opposed to the commensal type that 
binds to tri-mannose receptors [Johnson & Russo, 2005]. P-fimbriae are known for 
their enhanced ability to bind to the colon and remain in the gastrointestinal tract for 
an extended period. Following this, they confer the ability to spread to the perineum 
and urinary tract, causing ascending infections [Sobel & Kaye, 2004]. The allelic 
variation in the papG gene, which encodes for the adhesin at the tip of these fimbriae, 
produces variants that preferentially bind to different Gal (P 1-4) Gal-containing 
glycolipids. Because these glycolipids are distributed differenfially throughout the 
body, only certain pap-G variants contribute to disease in specific anatomical sites 
[Johnson & Russo, 2005]. Two of the four pap-G adhesin classes are associated with 
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UTIs, with class II mainly in pyelonephritis and class III in strains causing cystitis 
[Marrs et al., 2005]. In addition to molecules that aid in adherence, UPEC produce 
toxins that enhance infectivity. Cytotoxic necrotizing factor I (CNF-1) is a protein that 
induces host cell cytoskeleton rearrangement by permanently stimulating the Rho 
protein. By modifying the permeability of uroepithelium, bacteria are able to invade 
these cells, avoiding host defenses and antibiotics [Emody, 2000]. In addition to CNF-
I, UPEC may also produce P-hemolysin, a toxin that facilitates invasion of host 
tissues and causes damage to renal tubules and epithelial and parenchymal cells 
[Marrs et al., 2005]. 
1.2.4 Routes of UTIs 
The incidence of UTIs differs greatly between the sexes, with infections occurring 
fourteen times more often in females than males [Prescott et al., 2002]. The means 
through which infection begins greatly influences the differing rates between women 
and men. UTIs can occur in one of three ways: via the ascending route, the 
hematogenous route, or the lymphatic route. The ascending route is undoubtedly the 
most common route of infection. Bacteria from the normal flora of the colon are 
regularly excreted in fecal matter, and pathogenic strains may travel to the nearby 
periurethral area where they enter the urinary tract and cause ascending infection. The 
close proximity of the urethral meatus to the anus puts females at greater risk for 
UTIs. Sexual intercourse is indicated as a predisposing factor for ascending UTIs, as 
conforms that colonize the vaginal introitus may be transferred to the urethral opening 
during sexual activity [Sobel & Kaye, 2004]. The male anatomy greatly reduces the 
risk of UTI among men; however, infections are seen in small numbers. Rectal 
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intercourse puts men at increased risk for a UTI, while a lack of circumcision may also 
play a role [Bergan, 1997]. The hematogenous route of infection is far less common 
and limited only to infection of the kidneys, where blood-borne pathogens enter and 
contribute to the formation of abscesses. These infections are almost exclusively 
caused by bacteremic Staphylococcus species, with E. coli infections being virtually 
non-existent. There is little evidence to indicate the importance of infection via the 
lymphatic route, however due to the presence of direct lymphatic channels between 
the intestines and the kidneys, their role in producing upper tract infections cannot be 
ruled out entirely [Kunin, 1987; Sobel & Kaye, 2004]. 
1.2.5 Pathogenic bacteria implicated 
1.2.5.1 Escherichia coli 
E. coli can remain in the urinary tract by adhering to the epithelial receptor cells 
lining the UT and are able to avoid elimination by the flushing action of voided urine. 
They possess various virulence factors such as (1) fimbriae or pilli (2) haemolysin (3) 
aerobactin and (4) exotoxins and other features. Fimbriae or pilli are highly 
specialized surface glycoprotein projections that serve as ligands for glycoprotein and 
glycolipid receptors on uro-epithelial cells in the bladder, urethra and the vagina 
[Bannister et al., 2000]. Haemolysin degrades renal tubular red cells [Duse & 
Klugman, 1993; McClane & Mietzner, 1999]. Aerobactin is a sidophore that enhances 
iron acquisition and chelation Puse & Klugman, 1993; McClane & Mietzner, 1999; 
Hooton, 2000]. Other virulence features include the capsular acid polysaccharide 
antigen that appear, together with exotoxins, to assist in localization of organisms in 
the kidney to cause renal damage and are associated with pyelonephritis and inhibition 
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of phagocytosis [Jarlier et al., 1988; McClane & Mietzner, 1999]. Although most E. 
coll can cause UTIs, the disease is most commonly associated with specific serotypes 
other than those associated with gastrointestinal tract [Mims et al., 1993]. 
1.2.5,2 Klebsiella pneumoniae 
K. pneumoniae are opportunistic pathogens frequently associated with community 
acquired infections such as primary lobar pneumonia in immunocompromised and 
other high risk patient groups and 8-13% of cases of UTIs are attributed to infection 
by K. pneumoniae [Murray et al., 1998]. It is also known to be a major cause of 
nosocomial infections and infections of wound and soft tissues [Vaara & Vaara, 1983; 
Murray et al., 1998]. Alcoholics, people with compromised pulmonary function, and 
other patients in high-risk groups (patients with central venous and urinary tract 
catheters, patients on mechanical ventilation, etc.) are also at risk of being infected 
with K. pneumoniae [Jarlier et al., 1988; Weiner et al., 1999; Rebuck et al., 2000; 
Lautenbach et al., 2001]. Several factors contribute to the virulence ofK. pneumoniae: 
(1) the presence of cell wall receptors enable the organism to attach to host cells and 
protect the bacteria from phagocytosis and intracellular killing by polymorphonuclear 
leukocytes, (2) an extensive polysaccharide capsule (K antigen) protects the bacterial 
cell from phagocytosis and directly suppresses the immune response [Mims et al., 
1993; Hooton, 2000], (3) production of long chain-0-antigen polysaccharide in the 
endotoxin of the outer membrane that may contribute to resistance by inhibiting 
complement-mediated serum killing, and (4) the possession of a large plasmid (180 
kb) that encodes aerobactin (a protein involved in iron acquisition and regulation of 
the mucoid phenotype). 
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1.2.6 Isolation and identiflcation of UTIs 
The urinary tract as well as the urine secreted in the kidneys and the bladder is 
bacteriologically sterile. However, the urethral meatus and surrounding perineum are 
colonized with a mixture of skin and bowel flora so that normal voided urine may 
contain small numbers of bacteria [McClane & Mietzner, 1999; Bannister et al., 
2000]. A number of screening techniques have been developed for the rapid detection 
of UTI with mid-stream urine as the most suitable specimen. These techniques involve 
application of dipsticks to detect glucose, blood, protein, nitrite and leucocyte esterase. 
Other tests include semi-quantitative bacterial culture, where infection is usually 
indicated if colony counts >10*/L. The diagnosis of a UTI is confirmed by 
demonstrating the presence of an etiologic agent, which usually is a bacterium in the 
urine [Virella, 1997]. The purity of the culture is also important as a mixed culture is 
likely to indicate a contaminated specimen. For most clinical situations, simple or 
presumptive identification is sufficient, e.g. a lactose fermenting organism capable of 
indole production with a characteristic colonial morphology may be labeled a 
coliform. Checkerboard matrices may also provide simple presumptive and accurate 
species identification [Collee et al., 1996]. Commercial identification systems, semi-
automated and automated, produce a species or genus identification by use of a 
computer database [Bannister et al., 2000]. An illustration of flow chart method for 
manual identification of genera and species of Enterobacteriaceae is given in Figure 
1.2 [Taken fi-om Collee et al., 1996]. 
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1.2.7 Recommended treatment regimens of UTIs 
The morbidity associated with UTIs makes treatment of these infections a 
necessity. When choosing an appropriate agent to combat these infections, there are 
several factors for clinicians to consider. First, the drug of choice should have good in 
vitro and in vivo activity against many of the organisms known to cause UTIs, not just 
against E. coli. Additionally, the agent should be able to achieve high and prolonged 
concentrations in the urine and surrounding urinary tract tissues without loss of 
activity [Bergan, 1997; Jancel & Dudas, 2002]. In terms of the patient's well being, 
drugs should have the fewest and mildest side effects possible, with minimal effects 
on normal colonic and vaginal flora [Sobel & Kaye, 2004].Treatment of 
uncomplicated UTIs have in the past included aminopenicillins (amoxicillin, 
ampicillin), first generation cephalosporins (cephalothin, cefazolin), second generation 
cephalosporins (cefoxitin, cefuroxime), third generation cephalosporins (cephotaxime, 
ceftriaxone, ceftazidime), sulfamethaxazole-trimethoprim combinations 
(cotrimoxazole), amoxicillin/ clavulanic acid (augmentin), and recently, the 
flouroquinolones such as ciprofloxacin [Duse & Klugman, 1993; Hindler et al., 1994; 
Abdel-Rahman & Keams, 1998; Bannister et al., 2000]. 
1.2.7.1 Penicillins 
In 1929, the discovery of penicillin by Alexander Fleming revolutionized the 
world of infectious diseases. By 1949, penicillin was isolated in a relatively pure form, 
in sufficient quantities to treat a number of bacterial infections. The crucial point in the 
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Figure 1.2. Flow chart showing the LOGIC system for identification of Gram negative 
bacilli isolated from urine (Taken from Collee et al., 1996). 
The LOGIC scheme includes tests for lysine and ornithine decarboxylation, indole 
production, glucose and cellobiose fermentation and urease production. 
(*) Salmonella and Serratia species are distinguished by additional biochemical and 
serological tests. 
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history of this drug class came in 1945, when the basic chemical structure of all 
penicillins was revealed as a bicyclic B-lactam-thiazoIidine nucleus with variable side 
chains. The B -lactam ring holds the key to the drug's antibacterial activity, while the 
side chain determines the spectrum of activity for each particular penicillin compound 
[Preston & Drusano, 1999]. Penicillins exert their antibacterial properties by 
interfering with peptidoglycan synthesis, which compromises cell wall integrity, 
leading to cell death. Penicillins inhibit the cross-linking of N-acetylmuramic acid 
residues of adjacent peptidoglycan strands during the final step of peptidoglycan 
synthesis by acting as structural analogues of acyl-D-alanyl-D-alanine and competing 
for the active site of the enzyme transpeptidase. In doing so, they prevent the cross-
linking of peptidoglycan precursors, thereby disrupting cell wall stability [Preston & 
Drusano, 1999; Mascaretti, 2003]. In addition to transpeptidases, penicillins bind to a 
variety of other bacterial enzymes, collectively known as penicillin-binding proteins 
(PBPs). In E. coli, eight PBPs have been described, including carboxypeptidases and 
endopeptidases, all of which are important in cell wall formation and maintenance 
[White, 2000]. While the original, natural penicillins demonstrated excellent activity 
against Gram-positive organisms, they had very limited activity against Gram-
negative pathogens, including E. coli. The aminopenicillins were synthesized to 
overcome this problem. With the addition of an amino group to the fused 6-lactam-
thiazolidine nucleus, aminopenicillins exhibited enhanced penetration into Gram-
negative bacteria, such as E .coli, while retaining activity against gram-positive UTI 
pathogens, such as Enterococcus spp. and Staphylococcus saprophyticus, making 
them ideal agents for the treatment of UTIs [Yao et al., 1999]. 
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1.2.7.2 Sulfonamides and trimethoprim 
When coadministered, trimethoprim and sulfamethoxazole (TMP/SMX) are 
bactericidal agents with excellent antibacterial activity. Used in combination to treat 
UTI since 1968, TMP/SMX interferes with bacterial folate metabolism, by 
sequentially blocking the formation of tetrahydrofolic acid (THF). SMX is a structural 
analogue of paminobenzoic acid (PABA), the substrate for the enzyme 
dihydropteroate synthetase (DHPS), used to make dihydropteroic acid in the first step 
of THF synthesis. SMX preferentially binds to DHPS over PABA, thereby blocking 
the formation of dihydropteroic acid (DHP), which is needed to form dihydrofolic acid 
(DHF) in a later step along the THF synthesis pathway. TMP is a structural analogue 
of the pteridine moiety of DHF and preferentially binds to dihydrofolic acid reductase 
(DHFR), the enzyme normally responsible for the conversion of DHF to THF. By 
creating a sequential blockade in the formation of THF, TMP/SMX eliminates the 
thymidine pool required for DNA synthesis, leading to bacterial cell death [Goldstein 
&, Stein, 1999; Mascaretti, 2003]. Its low cost, high absorption, oral availability, 
extended half-life, and activity against Gram-positive and Gram-negative organisms 
has made TMP/SMX the first choice for empiric treatment of upper and lower UTIs 
[Goldstein & Stein, 1999; Gupta & Stamm, 2002]. 
1.2.7.3 Fluoroquinolones 
A relatively modem class of drugs, fluoroquinolones are becoming increasingly 
popular in the treatment of UTI due to their broad spectrum of activity and rapid 
bactericidal effects. The prototype for modem day quinolones, nalidixic acid, was 
discovered in 1962 as a byproduct of the formation of the anti-malarial dmg 
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chloroquine. The 1980s brought about the synthesis of the second-generation 
quinolones, the fluoroquinolones, including ciprofloxacin and levofloxacin, which 
have the broad spectrum of Gram-negative activity of the first generation quinolones 
as well as improved activity against Gram-positive organisms [Zhanel et al., 2002]. 
The fluoroquinolones exhibit their action on bacterial cells by interacting with DNA 
gyrase and topoisomerase IV, inhibiting their ability to regulate the topological state of 
DNA during replication, transcription, and repair. The tetrameric DNA gyrase protein 
is composed of two "A" subunits, which produce and re-seal strand breaks in the 
chromosome during replication, and two "B" subunits, which introduce negative 
supercoils into the strand of DNA. Second-generation quinolones act primarily by 
binding to the DNA-DNA gyrase complex formed during replication, preventing the A 
subunits from resealing strand breaks in the bacterial chromosome. Topoisomerase IV 
plays an integral role in chromosome segregation during bacterial cell division in 
addition to its role in relieving the DNA molecule of torsional strain. While the details 
of quinolone interactions with Topoisomerase IV are not as well understood, the 
importance of its loss of function must not be overlooked [Mulholland, 1996; Zhanel 
et al., 2002]. With their excellent bioavailability when orally administrated, good 
tissue penetration, low incidence of side effects and broad spectrum of activity, 
fluoroquinolones are prescribed to combat a variety of clinical infections and are 
especially favored in combating complicated UTIs [Mulholland, 1996; Mascaretti, 
2003]. 
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1.2.1 A B-Lactam antibiotics 
p-Lactam antibiotics form a large group of different compounds containing a P-
lactam nucleus. Different groups within the family are distinguished by the structure 
of the ring and the side chain attached to the p-lactam nucleus (Figure 1.3). Penicillins 
differ from cephalosporins in having a 5- membered thiazolidine ring complex and 
cephalosporins contain a 6-membered dihydrothiazine B-lactam ring complex [Dever 
& Dermody, 1991] (Figure'1.3). Since the discovery of P-lactam antibiotics in 1928 by 
Alexander Fleming [Rolinson, 1998], developments have led to the synthesis of semi-
synthetic compounds that can be divided into bicyclic penicillins, cephalosporins, 
monocyclic monobactams, and p-lactamase inhibitor combinations [Hamilton- Miller, 
1999] (Figure 1.3). P-Lactam antibiotics are commonly prescribed and have a wide 
spectrum clinical use because of low toxicity and strong bactericidal activity 
[Gruneberg, 1994; Petrosino et al., 1998]. They can be used in higher dosages for 
treatment of more severe infections and UTIs [Sanders & Sanders, 1992]. The primary 
targets for p-lactam antibiotics are the penicillin-binding proteins (PBPs), consisting 
of transpeptidases and carboxypeptidases responsible for creating cross-linkages 
between peptide chains. Following penetration of the bacterial cell surface, P-lactam 
antibiotics attach to the PBPs, to form a P-lactam- PEP complex. Catalytic activity is 
lost and cell wall synthesis and division interrupted [Richmond, 1981; Essack, 
Alexander & Pillay, 1994; Prober, 1998; Wright, 1999]. The anti-bacterial effect of all 
P-lactam antibiotics depends on the capacity of the antibiotic to diffuse through the 
cell membrane of the bacterial cell, the affinity of the antibiotic for its target proteins 
(the PBPs anchored in the cytoplasmic membrane of the bacterium) and the stability of 
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the antibiotic against bacterial degradation complex system [Dever & Dermody, 1991; 
Pitout et al., 1997]. P- Lactam antibiotics inhibit the cross linking (final stage) of 
peptidoglycan or murein synthesis of actively dividing bacterial cells (Figure 1.4) 
[Gould & Mackenzie, 1997]. Three PBPs oiE. coli have been shown to be targeted by 
6-lactam agents: PBP- 1, PBP-2 and PBP-3. Inhibition of PBP-IA and IB is 
associated with rapid killing and lysis of bacterial cell, inhibition of PBP-2 results in 
cell wall deficient spherical non-growing cells, and inhibition of PBP-3 cause lysis as 
well as filamentous changes [Bryan & Godfrey, 1991; Georgepapadakou, 1993; 
Katsanis et al., 1994; Gould 8c Mackenzie, 1997]. P-lactam antibiotics can also inhibit 
bacterial growth by mechanisms that do not solely involve the inhibition of cell wall 
synthesis. Inhibition of the formation of cell wall precursor by these agents can result 
in autolysis through the unsuppressed activity of murein hydrolases [Dever & 
Dermody, 1991]. Murein hydrolases are autolytic enzymes that cause nicks in the cell 
wall to provide sites for new peptidoglycan synthesis during cell wall enlargement. 
The inhibition of cell wall synthesis by P-lactam antibiotics does not alter the activity 
of these enzymes; therefore, bacterial autolysis can result fi-om the effects of osmotic 
pressure on the cell wall damaged by murein hydrolases [Wright, 1999]. 
Introduced in the 1960s cephalosporins are widely used routinely in many 
preoperative procedures, because of their broad-spectrum effectiveness and low 
toxicity (SAML supplement). Cephalosporins are classified according to the route of 
administration and their in vitro anti-bacterial spectra [Bannister et al., 2000]. 
Currently there are four generations of agents, each succeeding a generation 
possessing a greater spectrum of activity. The antibacterial activity of cephalosporins 
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depends on their ability to penetrate the bacterial cell wall, resist inactivation by |3-
lactamases and bind to and inactivate PBPs. Resistance can, however, develop at each 
of these steps [Prober, 1998]. Expanded-spectrum cephalosporins were specifically 
designed and introduced into clinical practice in the early 1980s, being resistant to 
hydrolysis by the older broad-spectum p-lactamases commonly encountered at that 
time, i.e. p- lactamases such as TEM-1, TEM-2 and SHV-1 [Pitout et al., 1998]. Some 
of the well-known agents include cefotaxime, ceftazidime and ceftriaxone [Heritage et 
al., 1999]. 
1.3 History of antibiotic development 
In order to comprehend the problem of antibiotic resistance as it exists today, it is 
useftil to understand the history and development of both antibiotics and antibiotic 
resistance. Antimicrobial drugs have generally been classified into two categories; one 
includes the synthetic drugs, such as the sulfonamides and the quinolones, and the 
second, antibiotics, synthesized by microorganisms. In recent years, increasing 
numbers of semi-synthetic drugs have been developed which are chemical derivatives 
of antibiotics, thereby blurring the distinction between synthetic and natural 
antibiotics. Interest in antimicrobial chemotherapy was kindled as soon as 
microorganisms were understood to be agents of infectious disease. In earlier times, 
plant products were sometimes used successfiilly in the treatment of disease, but 
neither doctors nor patients knew the basis for the action of these therapeutic agents. 
Many early medicines were used to cure protozoan diseases, rather than bacterial 
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Figure 1.3: Structure of P-lactam antibiotics witli sites for enzymatic degradation of 
penici 11 ins/cephalosporins. 
A=Classical penam and cepham ring resoectively [also known as thiazolidine ring in 
basic structure], B= Four membered P-lactam ring [azetidinone], shared by all 
compounds; it remains unmodified (Hamilton-Miller, 1999), R= Acyl side chain, 
varies according to specific agent. 
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Figure 1.4: The consequences of the interruption of peptidoglycan synthesis, such as 
caused by penicillins and cephalosporins (Richmond, 1981). 
1. Normal rod-shaped bacterium. 
2. Inhibition of peptidoglycan biosynthesis leads to a weakening of the cell walls. This 
is often first seen at the point where the next division fiirrow would become 
apparent were growth to continue normally. 
3. The cell bursts. 
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diseases. As early as 1619, it was known that malaria could be treated with the extract 
of cinchona bark (quinine) and that amoebic dysentery could be treated with 
ipecacuanha root (emetine) [Garrod et al., 1971; Greenwood et al., 2000]. Only a few 
antibacterials, such as mercury, which was used to treat syphilis, were in use when the 
era of true chemotherapy began. It was in the early 1900's when Paul Ehrlich first 
hypothesized that dyes could be used as antimicrobial drugs, based on their differential 
affinities for various tissues. In 1904, Ehrlich and Shiga discovered that a red dye 
called trypanrot was effective against trypanosomes [Mitsuhashi et al., 1993]. It was 
around this time that arsenicals drew Ehrlich's interest. Ehrlich, along with Sahachiro 
Hata in 1909, found that arsphenamine (named Salvarsan) was active against 
spirochetes and, therefore, was an effective cure for syphilis [Greenwood et al., 
2000] .The first truly effective class of antimicrobial drugs were the sulfonamides, 
discovered by Gerhard Domagk [Domagk et al., 1935]. In 1932, two scientists at the 
Bayer company, Mietzsch and Klarer, synthesized Prontosil red, a red dye bound to a 
sulfonamide group. Domagk [Domagk et al., 1935] showed, in 1935, that infections in 
mice caused by hemolytic streptococci were cured by Prontosil red [Garrod et al., 
1971; Greenwood et al., 2000]. Unfortunately for Bayer, Prontosil red was shown to 
have no antibacterial activity in vitro. This lack of activity was explained by Trefouel 
et al. [Trefouel et al., 1935] when they showed that Prontosil red is split in vivo into its 
component dye and sulfanilamide, the active antibacterial agent and a previously 
described molecule that was already in the public domain. From that point, 
sulfanilamide was manufactured by a number of companies and work was begun to 
modify the molecule to enhance performance, leading to decreased side effects and a 
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broader spectrum of action. Although peniciUin was the first natural antibiotic to be 
discovered, the idea of using microorganisms therapeutically was not new. Fungi had 
been used in poultices for many years, and by 1899, a product called pyocyanase, 
which was an extract from Pseudomonas aeruginosa, was used in the treatment of 
wounds [Garrod et al., 1971]. Penicillin was first isolated from Penicillium notatum in 
1928 by Alexander Fleming [Fleming et al., 1929], but he was unable to isolate and 
purify enough drug to be of any use. After a worldwide search for Penicillium strains 
that could produce more penicillin, Raper and Fennel [Raper et al., 1946] found a 
strain of Penicillium chrysogenum on a moldy cantaloupe at a local market that was 
capable of even higher yields of penicillin [Demain et al., 1999]. 
A series of different antibiotics were quickly discovered after penicillin came into 
use. In 1940, Selman Waksman began searching for antibiotic compounds produced 
by soil microorganisms [Greenwood et al., 2000]. In 1943, one of Waksman's students 
discovered streptomycin [Schatz et al., 1944], leading to a flood of researchers 
combing the world for new drugs. It was in this same period that Rene Dubos 
[Hotchkiss et al., 1941] discovered gramicidin, the first antibiotic active against gram-
positive bacteria. Chlortetracycline, chloramphenicol, and others were discovered 
shortly thereafter [Garrod et al., 1971]. Many discoveries were of drugs that were too 
toxic for human use, or that had already been discovered. Nevertheless, this work did 
lead to many new drugs and within only 10 years, drugs comprising the major classes 
of antibiotics were found [Greenwood et al., 2000]. In addition to soil, many of these 
drugs were discovered by isolating the producing microorganisms from interesting and 
unusual sources. For example, some antibiotic-producing bacteria were isolated from a 
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wound infection and otiiers from sewage, a chicken's throat, and a wet patch of wall in 
Paris [Garrod et al., 1971]. In 1962, one of the later discoveries was a synthetic drug, 
nalidixic acid, the first of the quinolones to be described, and although not 
therapeutically important by itself, modification of nalidixic acid led to the production 
of the highly effective fluoro-quinolones. Members of this class, such as ciprofloxacin, 
norfloxacin, enrofloxacin, and ofloxacin, have become very important in the treatment 
of diseases in both humans and animals [Mitsuhashi et al., 1993]. Since the 1960's, 
there have been few discoveries of new antibiotic drugs. The drugs developed since 
have mostly been chemical modifications of existing drugs. These modifications have 
been very useful in treating infectious diseases, leading to enhanced killing of 
pathogens, increased spectrum of action, reduced toxicity, and reduced side effects. 
Unfortunately, since the 1970's, only one new class of antibiotics has been introduced 
[Lipsitch et al., 2002] and a recent trend in antibiotic therapy has been to employ 
combinations of drugs with different mechanisms of action, in order to increase their 
effectiveness and to overcome the problem of drug resistance. 
1.4 IMechaiiisms of antibiotic action and resistance 
There are several major classes of antibiotics that can be categorized based on 
their mode of antibacterial action. In general, antibiotics can be defined as those that 
inhibit cell wall synthesis, those that inhibit protein synthesis, and those that inhibit 
nucleic acid synthesis. See table 1.1 for a summary of the major antibiotic classes. The 
selective toxicity of antibiotics lies in the differences in cellular structures between 
eukaryotic and prokaryotic cells. However, differences in cellular structure among 
bacterial species can lead to resistance to certain antibiotics. The definition of bacteria 
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Table 1.1. Major classes and examples of antibiotics. 
Cell wall 
synthesis 
Protein 
synthesis 
Nucleic 
acid 
synthesis 
B-lactams 
Penicillins 
Cephalosporins 
Carbapenems 
Aminoglycosides 
Streptomycin 
Neomycin 
Kanamycin 
Gentamicin 
Sulphonamides 
(diaminopyrimidines) 
Sui famethoxazole-
trimethoprim 
Glycopeptides 
Vancomycin 
Avopuricin 
Chloramphenicol 
Quinolones 
Ciprofloxacin 
Norfloxacin 
Tetracyclines Macrolides 
Erythromycin 
Azythromycln 
Clarithromycin 
Streotogramins 
Vlrginiamycin 
Quinopristin 
Dalfopristin 
Pristinamycin 
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as resistant or susceptible is critical for clinicians. It is also very important to note the 
difference between intrinsic and acquired resistance to an antibiotic. Intrinsic 
resistance can best be described as resistance of an entire species to an antibiotic, 
based on inherent (and inherited) characteristics requiring no genetic alteration. This is 
usually due to the absence of a target for the action of a given antibiotic or the inability 
of a specific drug to reach its target. For example, mycoplasmas are always resistant to 
N-lactam antibiotics since they lack peptidoglycan (which the N-lactams act upon). 
Similarly, the outer membrane of gram negative cells can prevent an antibiotic from 
reaching its target. For example, Pseudomonas aeruginosa exhibits high intrinsic 
resistance to many antibiotics due to its drug efflux pumps and restricted outer 
membrane permeability. Acquired resistance can arise either through mutation or 
horizontal gene transfer. Presence of the antibiotic in question leads to selection for 
resistant organisms, thereby shifting the population towards resistance. 
Mechanisms of antibiotic resistance and the over coming methods are thus an 
intense area of research. Several mechanisms of antimicrobial resistance are readily 
spread to a variety of bacterial genera. First, the organism may acquire genes encoding 
enzymes, such as P-lactamases, that destroy the antibacterial agent before it can have 
an effect. Second, bacteria may acquire efflux pumps that extrude the antibacterial 
agent from the cell before it can reach its target site and exert its effect. Third, bacteria 
may acquire several genes for a metabolic pathway which ultimately produces altered 
bacterial cell walls that no longer contain the binding site of the antimicrobial agent. 
Fourth, bacteria may acquire mutations that limit access of antimicrobial agents to the 
intracellular target site via down regulation of porin genes [Tenover et al., 2006]. 
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Thus, normally susceptible populations of bacteria may become resistant to 
antimicrobial agents through mutation and selection, or by acquiring from other 
bacteria the genetic information that encodes resistance. Acquired resistance that 
develops due to chromosomal mutation and selection is termed vertical evolution. 
1.4.1 Inhibitors of cell wall synthesis 
There are two major groups of cell wall synthesis inhibitors, the N-lactams and 
the glycopeptides. As bacterial cell walls are wholly unlike the membranes of 
eukaryotes, they are an obvious target for selectively toxic antibiotics. The N-lactams 
include the penicillins, cephalosporins, and the carbapenems. These agents bind to the 
penicillin binding proteins (PBP's) that cross-link strands of peptidoglycan in the cell 
wall. In gram negative cells, this leads to the formation of fragile spheroplasts that are 
easily ruptured. In gram positive cells, autolysis is triggered by the release of 
lipoteichoic acid [Greenwood et al., 2000]. 
1.4.1.1 Mechanism of N-Iactam resistance 
N-lactamases play a major role in the development of N-lactam resistance. These 
enzymes catalyze hydrolysis of the N-lactam ring and, thereby, inactivate these 
antibiotics. Many bacteria contain chromosomal ly encoded N-lactamases necessary 
for cell wall production and it is only through over-production of these enzymes that 
resistance occurs [Greenwood et al., 2000]. N-lactamases encoded on plasmids or 
other transmissible elements can lead to such overproduction and, therefore, to 
resistance [Normark et al., 2002]. There are also some bacteria that possess altered 
PBP's that result in reduced penicillin binding [Greenwood et al., 2000]. Since the 
discovery of penicillin and resistant bacteria, various new versions of the N-lactams 
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have been used that have different spectrums of activity and different susceptibility to 
N-lactamases. Since the 1970s, several compounds, such as clavulanic acid, have been 
discovered that have the ability to bind irreversibly to N-Iactamases and, thereby, 
inhibit their action. Combinations of these compounds with N-lactam drugs have been 
very successfiil in treatment of disease [Bryan et al., 1984]. The glycopeptides are a 
group of antibiotics that include vancomycin, avoparcin, and others that bind to acyl-
D-alanyl-D-alanine. Binding of this compound prevents the addition of new subunits 
to the growing peptidoglycan cell wall. These drugs are large molecules that are 
excluded from gram negative cells by the outer membrane, thus limiting their action to 
gram positive organisms. 
1.4.1.2 Glycopeptide resistance 
Glycopeptide resistance was long thought to be rare, but has recently been shown 
to be quite common [Bryan et al., 1984]. Resistance in enterococci has developed 
through newly discovered enzymes that use D-alanyl-D-lactate in place of acyl-D-
alanyl-D-alanine, allowing cell wall synthesis to continue. Other mechanisms of 
resistance involve the over-production of peptidoglycan precursors which overwhelm 
the drug [Greenwood et al., 2000]. 
1.4.2 Inhibitors of protein synthesis 
There are many types of antibiotics that inhibit bacterial protein synthesis. These 
drugs take advantage of structural differences between bacterial ribosomes and 
eukaryotic ribosomes. The aminoglycoside antibiotics are a group whose mechanism 
of action is not completely understood. The three major groups of aminoglycosides are 
the streptomycins, neomycins, and kanamycins. These drugs enter bacterial cells by an 
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active transport that involves quinones that are absent in anaerobes and streptococci, 
thus excluding these organisms from the spectrum of action. Streptomycins act by 
binding to the 308 ribosomal subunit. Kanamycins and neomycins bind to both the 
508 subunit and to a site on the 308 subunit different from that of streptomycin 
[Greenwood et al., 2000]. Activity involving initiation complexes and cell membrane 
proteins that contribute to ceJi death plays a role in the action of these antibiotics, but 
this is poorly understood [Bryan et al., 1984; Greenwood et al., 2000]. There are three 
mechanisms of aminoglycoside resistance that have been identified to date. The first 
involves only streptomycin. Since streptomycin binds to one particular protein on the 
ribosome, alteration of this protein, even by a single amino acid in its structure, 
confers high-level resistance to the drug [Bryan et al., 1984]. The other mechanisms 
involve decreased uptake of the antibiotic and in one of these the cell membrane is 
altered, preventing active transport of the drug, hi the other, one of many enzymes 
alters the antibiotic as it enters the cell, causing a block in fiirther active transport 
[Bryan et al., 1984]. Chloramphenicol is a broad-spectrum antibiotic that, although 
naturally occurring, is produced by chemical synthesis. Chloramphenicol inhibits 
peptide bond formation on 70S ribosomes [Bryan et al., 1984]. This drug is especially 
useful in that it can penetrate eukaryotic cells and cerebrospinal fluid, making it a drug 
of choice for treatment of meningitis and intracellular bacterial infections such as 
those caused by chlamydia. It is not in widespread use, however, because of 
potentially fatal side-effects, namely, aplastic anemia [Greenwood et al., 2000]. 
Resistance to chloramphenicol is conferred by the enzyme chloramphenicol acetyl-
transferase. A number of these enzymes have been discovered, each altering the 
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chloramphenicol molecule to prevent binding to the bacterial ribosome. 
Chloramphenicol resistance in gram negative cells can also arise from alteration in 
outer membrane permeability that prevents the drug from entering the cell [Bryan et 
al., 1984]. 
The tetracyclines are another group of broad-spectrum antibiotics that inhibit 
bacterial protein synthesis. They are brought into the cell by active transport and, once 
there, bind to the 308 subunit to prevent binding of aminoacyl tRNA [Roberts et al., 
1996]. Resistance to the tetracyclines occurs via three mechanisms. First, production 
of a membrane efflux pump removes the drug as rapidly as it enters and there are 
several genes encoding these pumps. Second, several ribosome protection proteins act 
to prevent tetracycline from binding to the ribosome, thus conferring resistance. Third, 
a protein found only in Bacteroides spp. enzymatically inactivates tetracycline 
[Roberts et al., 1996]. Interestingly, efflux pump inhibitors have recently been 
discovered that may allow combinations of these inhibitors and tetracyclines to be 
used against previously resistant strains [Chopra et al., 2002]. The macrolides are a 
group of antibiotics commonly used to treat gram positive and intracellular bacterial 
pathogens. Erythromycin was the first of these, and several other important macrolides 
have been discovered since, including clarithromycin and azithromycin. Azithromycin 
has a longer plasma half-life which allows treatment with a single dose for some 
pathogens or a once daily dose for others. Clarithromycin has enhanced absorption and 
causes less gastrointestinal discomfort [Gaynor et al., 2003]. It was originally believed 
that erythromycin inhibited protein synthesis by competing with amino acids for 
ribosomal binding sites, but newer research shows several mechanisms are involved 
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[Garrod et al., 1971]. The macrolides are now believed to promote dissociation of 
tRNA from the ribosome, inhibit peptide bond formation, inhibit ribosome assembly, 
and prevent amino acid chain elongation [Gaynor et al., 2003]. There are two major 
mechanisms of macrolide resistance. First, an efflux pump has been found that 
removes the drug from the cell. Second, modification of the ribosome can confer 
resistance. Mutations at several sites of the ribosome can allosterically prevent 
macrolide binding and a common alteration is dimethylation of one nucleotide on the 
23S rRNA. This dimethylation not only prevents macrolide binding, but also confers 
resistance to lincosamide and streptogramin antibiotics [Gaynor et al., 2003]. The 
streptogramins are another class of antibiotic that inhibits bacterial protein synthesis, 
mostly in gram positive organisms (due to decreased permeability of the gram 
negative outer membrane). These antibiotics are actually combinations of structurally 
different drugs, types A and B that act synergistically. These compounds bind to 
separate sites on the SOS subunit. Type A drugs block attachment of subsfrates at two 
sites on the SOS subunit, whereas type B drugs cause release of incomplete protein 
chains. The synergistic effect arises from a conformational change induced by the 
binding of a type A drug which significantly increases affinity of type B drugs 
[Johnston et al., 2002]. Streptogramins currently in use include virginiamycin, 
pristinamycin, and quinupristin/dalfopristin. Resistance to sfreptogramin antibiotics 
can be found in several forms. Efflux pumps for both type A and B streptogramins 
have been identified. Type A streptogramins can be inactivated by one of the 
virginiamycin acetyl-transferases, and several enzymes have been identified that can 
inactivate type B streptogramins. Alteration of bacterial ribosomal proteins or RNA 
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can also confer resistance. A common mutation is the dimethylation of one nucleotide 
on the 23 S rRNA, mentioned previously, that gives rise to resistance to type B drugs, 
as well as macrolides and lincosamides [Johnston et al., 2002]. 
1.4.3 Inhibitors of nucleic acid synthesis 
The sulfonamides and the diaminopyrimidines should be discussed together, in 
that both only indirectly inhibit nucleic acid synthesis by inhibiting folate synthesis. 
Folate is a coenzyme necessary for the synthesis of purines and pyrimidines. Although 
both types of drugs are useful on their own, they exhibit a synergistic effect when 
combined. Sulfonamides are currently not used commonly in medicine, but the 
combination drug trimethoprim-sulfamethoxazole is sometimes used in the treatment 
of urinary tract infections. Sulfonamides serve as an analog of p-aminobenzoic acid. 
Therefore, they competitively inhibit an early step in folate synthesis. 
Diaminopyrimidines, of which trimethoprim is the most common, inhibit 
dihydrofolate reductase, the enzyme that catalyzes the final step in folate synthesis 
[Greenwood et al., 2000]. There are several resistance mechanisms microorganisms 
employ against each of the anti-folate drugs. For example, sulfonamides are rendered 
ineffective by over-production of p-aminobenzoic acid or production of an altered 
dihydropteroate synthetase. The substrate for dihydropteroate synthetase is p-
aminobenzoic acid, and the altered form has a much lower affinity for sulfonamides 
than for p-aminobenzoic acid [Then et al., 1982]. Trimethoprim resistance can also 
result from several mechanisms, e.g., over-production of dihydrofolate reductase or 
production of an altered, drug-resistant form can lead to resistance [Bryan et al., 
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1984]. In addition, both drugs can be enzymatically inactivated, resulting in resistance 
[Thenetal., 1982]. 
The quinolones are a chemically varied class of broad-spectrum antibiotics widely 
used to treat many diseases, including gonorrhea and anthrax. Drugs in this class 
include nalidixic acid, norfloxacin, and ciprofloxacin. These drugs are commonly used 
and, worldwide, more ciprofloxacin is consumed than any other antibacterial agent 
[Acar et al., 1997]. Quinolones inhibit bacterial growth by acting on DNA gyrase and 
topoisomerase IV, which are necessary for correct functioning of supercoiled DNA 
[Greenwood et al., 2000]. Although quinolones target both enzymes, in gram negative 
organisms the primary target is DNA gyrase and, in gram positive organisms, the 
primary target is topoisomerase IV [Ruiz et al., 2003]. There are three main 
mechanisms of resistance to quinolones. Resistance to some quinolones occurs with 
decreased expression of membrane porins. Cross-resistance to other drugs requiring 
these porins for activity also results from these changes. A second mechanism of 
resistance is expression of efflux pumps in both gram negative and gram positive 
organisms [Novak et al., 1999] and the third is alteration of the target enzymes. 
Several mutations have been described in both quinolone target proteins that result in 
reduced binding affinities [Ruiz et al., 2003]. It is believed that high-level quinolone 
resistance is brought about by a series of successive mutations in the target genes, 
rather than a single mutation [Novak et al., 1999]. 
1.5 Genetic mechanisms of resistance 
Bacteria also develop resistance through the acquisition of new genetic material 
from other resistant organisms. This is termed horizontal evolution, and may occur 
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between strains of the same species or between different bacterial species or genera. 
Mechanisms of genetic exchange include conjugation, transduction, and 
transformation [McManus et al., 1997]. 
Transformation (Fig. 1.5) involves the passage of DNA to a recipient through a 
specific medium. This process of transferring genetic material is mostly observed in 
vitro in the molecular biology laboratory. 
Transduction (Fig. 1.5) is a process whereby DNA is transferred from a donor to a 
recipient by way of a host, a phage. It is still unknown whether this process causes 
clinically observed resistance to antibiotics. Because this process is highly dependent 
on specific phages, it may occur only within certain bacterial species. Only a limited 
amount of DNA that can be packed into the head of a phage can normally be 
transferred. Transduction therefore cannot be responsible for multiple drug resistance. 
Conjugation (Fig. 1.5) is the process when DNA transfers from a donor to a recipient 
by simple, direct cell-to-cell contact. The process allows for the passage of more than 
one functional gene at a time, so that multiple resistance could occur within a single 
step. Furthermore, many different organisms can act as recipients, allowing DNA 
(resistant genes) to be donated freely from different sources. Resistance can be passed 
from commensals in the gut to a pathogens existing in the same environment. 
Conjugation is thus an important and highly efficient process for transferring genes, 
and the acquisition of resistance by most pathogens is probably a result of this process. 
Other mobile genetic elements include transposons and integrons. 
Transposons are sequences of DNA that are capable of transposing or moving from 
one region to another or between plasmids and chromosomes. Transposons can 
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contain one or more genes, including those necessary for translocation, and often 
contain either resistance genes or genes necessary for degradative enzymes [Scott et 
al., 2002]. These genes are flanked by insertion sequences that allow insertion of the 
DNA into the chromosome or plasmid. 
Integrons are mobile elements that consist of conserved sequences of DNA bordering 
"cassettes" of genes. The conserved sequences contain the genes necessary for 
integration, promotion, and capture of cassettes. Gene cassettes are promoter-less units 
that contain the genes for antibiotic resistance or for virulence factors [Roe et al., 
2003]. Integrons are capable of carrying several gene cassettes and are associated with 
multiple antibiotic resistance and pathogenicity islands. In recent years, through the 
study of genomics, we have come to learn that horizontal gene transfer occurs far 
more widely and often then we ever imagined. As complete genomes have been 
sequenced, evidence is mounting that not only do bacteria share genes with one 
another, but transfer occurs between all three domains of life, the Archaea, Eubacteria, 
and Eukaryotes. In 1998, Lawrence and Ochman [Lawrence et al., 1998] showed that 
18% of the E. coli genome had been acquired through horizontal transfer. It has been 
shown that archaeal genes comprise 24% of the Thermatoga maritima genome. This is 
particularly surprising since T. maritime is thought to be among the slowest evolving, 
and on the deepest branch, of the Eubacteria [Nelson et al., 1999]. Eukaryotes 
apparently trade genes with bacteria as well. In an investigation of Deinococcus 
radiodurans, Makarova et al. [Makarova et al., 2001] found several eukaryotic genes 
including human, yeast, and fly genes, some of which have only ever been found in 
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eukaryotes. Mycobacterium tuberculosis has also been reported to contain eukaryotic 
genes [Gamieldien et al., 2002]. 
Plasmids are defined as a double stranded, circular or linear DNA molecule 
capable of autonomous replication. They are mostly a phenomenon of the prokaryotic 
world, although they exist in some groups of primitive eukaryotes as yeast, fungi and 
cellular slime moulds [Rush et al., 1985]. Plasmids are not organisms. They belong to 
a special biological category of extra-chromosomal, accessory DNA elements 
[Reanney et al., 1976, Campbell et al., 1981]. By definition, plasmids do not carry 
genes essential for growth of their host under no stressed conditions. Plasmids are a 
fashionable field of scientific research, since they are still studied as excellent models 
of DNA replication as well as in biotechnology. Natural plasmids have systems 
guarantying their autonomous replication but also mechanisms controlling the copy-
number and ensuring stable inheritance during cell division. Many plasmids can 
promote their horizontal transfer among bacteria of different genera and kingdoms, 
through the conjugation process. However, the presence of plasmids must have some 
biological cost for the bacterial host. It is therefore plausible that a selfish element that 
does not benefit its host can be eliminated from the bacterial population. The plasmid-
encoded functions have been extensively investigated and there is ample evidence that 
natural plasmids have evolved as an integral part of the bacterial genome, providing 
additional functions to their host [Thomas et al., 2005]. In many cases the selective 
advantage of a plasmid appears obvious, because it carries genes that confer a 
selectable phenotypic character under specific niche conditions [Lenski et al., 1998]. 
The best example of phenotypic advantage associated to a plasmid is given by the 
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antimicrobial resistance. Resistance genes located on plasmids offer immediate 
advantage to their host under antimicrobial pressure. However, the real advantage of 
the plasmid location of resistance genes is not evident: plasmid-located resistance 
genes can be successfully transferred to the bacterial chromosome, therefore 
disfavoring the plasmid maintenance. An advantage of plasmid location for selectable 
genes has been hypothesized in the relative higher copy number of plasmids, 
influencing the expression levels by increasing the gene dosage. However, there are 
numerous other factors influencing the chromosome/plasmid harmony and evolution. 
Plasmids must be thought like autonomous selfish molecules, encoding extra genetic 
information, establishing complex relationships with the recipient host and playing 
multiple roles in the bacterial population. Bacterial plasmid genome sequence 
comparisons provided the historical events through which plasmids are assembled. 
Their evolution seems to proceed by the assemblage of modular components by 
transposition, homologous recombination, and illegitimate recombinational events 
[Bennett et al., 2004]. This is particularly evident when the phenomenon of 
antimicrobial resistance is analyzed. Antimicrobial resistance arises from a complex 
multi-factorial process supported by panoply of mobile genetic elements that contain 
and transfer resistance determinants. Resistance genes located on plasmids move from 
one bacterium to another, conferring phenotypic characteristics. Several resistance 
plasmids have been described to carry virulence factors, such as bacteriocins, 
siderophores, cytotoxins, or adhesion factors [Martinez et al., 2002] and virulence 
plasmids have been described to carry resistance genes [Guerra et al., 2002, Villa et 
al., 2005, Herrero et al., 2006]. For plasmids carrying virulence and resistance linked 
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determinants, an infective population will be selected for antimicrobial resistance, and 
antimicrobial resistance pressure will select the virulence traits. However, once those 
determinants have been selected in the bacterial host, they can evolve further and 
eventually be transferred to other bacterial population. The acquisition of 
antimicrobial resistance genes on virulence plasmids, could represent a novel tool in 
bacterial evolution, implementing adaptive strategies to explore and colonize novel 
hosts and environments [Martinez et al., 2002]. 
Plasmid-mediated resistance to P-lactam antibiotics in E. coli is of major concern 
in hospitals. In South Africa this has resulted in widespread resistance of E. coli to 
ampicillin and co-trimoxazole, preventing their usage in urinary tract infections 
[Klugman, 1993]. Studies show that for both nosocomial and community acquired 
infections (such as UTIs), the mortality and morbidity in prolonged hospitalisation, are 
twice as high in patients infected with antibiotic-resistant strains than with susceptible 
strains [Pitout et al., 1997; Silva et al., 1999; Lautenbach et al., 2001]. Bacteria can 
possess plasmids that can code for more than one P-lactamase in addition to their 
expression of chromosomal enzyme. Due to carriage of plasmids and promiscuous 
exchange of such material between bacteria, these resistance genes have spread widely 
and are also subject to mutation [Lee, Yuen & Kumana, 2001]. Plasmid mediated |3-
lactamases were first recognized in Gram-negative bacteria in the early 1960s, shortly 
after the introduction of ampicillin [Livermore, 1993]. 
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1.6 Antibiotic resistance in UTIs 
While a number of drugs are available for UTI management, increasing resistance 
rates among infecting organisms have limited the use of a number of antibiotics, 
leading to greater difficulty in treating these infections. 
1.6.1 Resistance to aminopeniciilins 
The aminopeniciilins were the longstanding favorites in the treatment of UTI. 
However due to extraordinary resistance rates in uropathogens their usefulness is 
diminishing [MulhoUand, 1997]. In Gram-negative organisms, aminopenicillin 
resistance is largely due to the production of B-lactamases, secreted enzymes that 
destroy the B -lactam nucleus of penicillins [Preston & Drusano, 1999]. In contrast, 
modifications in PBPs play a major role in Gram-positive penicillin resistance, though 
in Gram-negative organisms such as E. coli, this is not a common occurrence 
[Quintilliani et al., 1999]. Presently, more than 35% of E. coli isolates in North 
America are resistant to aminopeniciilins, causing these once first-line antibiotics to be 
demoted to second- or third-line therapy for UTIs [Zhanel et al., 2005]. 
1.6.2 Resistance to TMP/SMX 
TMP/SMX remains the drug of choice for empirical treatment of uncomplicated 
UTIs in the U.S. as it has for over 20 years [Hooton, 2003; Burman et al., 2003]. 
However, increases in resistance to this drug combination in recent years may soon 
render it unsuitable for empiric treatment of UTI [Carrie et al., 2004]. In the 
Enterobacteriaceae, mechanisms of acquired resistance to SMX include a) 
hyperproduction of PABA, which competes with SMX for the active site of the 
enzyme DHPS; b) altered DHPS with decreased affinity for SMX; c) hyperproduction 
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of DHPS; and d) decreased membrane permeability to SMX. Similarly, resistance to 
TMP is attributed to either altered or hyperproduction of the enzyme DHFR. The 
widespread use of these compounds has led to the development of resistance in most 
bacterial species on a global scale [Goldstein & Stein, 1999]. Guidelines set by the 
Infectious Disease Society of America recommend fluoroquinolones for empiric 
therapy of UTI once TMP/SMX resistance levels exceed 20%, and such rates have 
been reported [Burman et al., 2003; Hooton, 2003; Zhanel et al., 2005]. This has led to 
a shift in prescribing for UTI, with TMP/SMX prescriptions dropping fi-om 48 to 24% 
between 1989 and 1998, and fluoroquinolone use increasing from 19 to 29% over the 
same period [Hooton, 2003]. 
1.6.3 Fluoroquinolone resistance 
While quinolone resistance rates in North America are relatively low, their 
increased popularity in recent years has led to a rise in resistance. Currently 
ciprofloxacin resistance rates in North American urinary E. coli isolates sit slightly 
above 5% [Zhanel et al., 2005]. The ability of Gram-negative organisms to prevent the 
cellular accumulation of fluoroquinolones has been documented. Resistant isolates 
utilize energy-dependent efflux pumps to remove fluoroquinolones from the cell while 
reducing porin channels to decrease diffusion into the cell [Mascaretti, 2003]. 
Additionally, chromosomal mutations in gyrA and parC result in altered DNA gyrase 
and topoisomerase IV, respectively, leading to decreased fluoroquinolone affinity 
[Zhanel et al., 2002; Mascaretti, 2003]. 
1.6.4 p-Lactam resistance 
There are three major ways bacteria avoid the bactericidal effect of P-lactams: 
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(a) Production of P-lactamases. p-Iactamases are bacterial enzymes that hydrolyze the 
P-lactam ring and render the antibiotic inactive before it reaches the PBP target. 
The underlying structural kinship that P-lactamases share with PBPs allows these 
enzymes to bind, acylate, and use a strategically located water molecule to 
hydrolyze and thereby inactivate the p-lactam [Massova et al., 1998]. 
(b) Altered PBPs that exhibit low affinity for P-Jactam antibiotics. Examples are PBP 
2x of Streptococcus pneumoniae and PBP 2' (PBP2a) of Staphylococcus aureus 
[Chambers et al., 1997]. These PBPs are relatively resistant to inactivation by 
penicillins and are able to assume the functions of other PBPs when the latter are 
inactivated. 
(c) Lack or diminished expression of outer membrane proteins (OMPs) in gram-
negative bacteria. The loss of OMPs restricts the entry of certain P-lactams into 
the periplasmic space of gram-negative bacteria and hence access to PBPs on the 
inner membrane. Imipenem resistance in Pseudomonas aeruginosa and K. 
pneumoniae can arise from the loss of OMP D2 and of OmpK36, respectively 
[Livermore et al., 2001; Gootz et al., 2004; Jacoby et al., 2004]. The destruction 
of P-lactams by p-lactamases is the most important resistance mechanism in 
gram-negative bacteria. 
1.6.5 Multi-drug resistance 
A current phenomenon of great concern in the medical community is the rise in 
multi-drug resistant organisms, defined as bacteria with simultaneous resistance to 
three or more different classes of antibiotics [Guyot et al., 1999]. In a recent survey of 
North American fluoroquinolone resistant uropathogens, more than 55% of E. coli 
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isolates exhibited additional resistance to ampicillin as well as TMP/SMX [Zhanel, 
Unpublished data]. Patients infected with such organisms experience significantly 
higher degrees of treatment failure, prolonging antibiotic usage and morbidity 
associated with infection [Gupta & Stamm, 2002; Sobel &. Kaye, 2004]. 
1.7 p-Lactamase classification and properties 
P-lactamases are globular proteins that characteristically have an a-helices, p-
pleated sheets, and share similar structural features. P-lactamases are categorized 
based on similarity in amino acid sequence (Ambler classes A through D) or on 
substrate and inhibitor profile (Bush-Jacoby-Medeiros Groups 1 through 4) (Table 1.2) 
[Ambler et al., 1980, Jaurin et al., 1981; Ouellette et al., 1987; Huovinen et al., 1991; 
Bush et al., 1995]. Ambler Class A enzymes (Bush Group 2) are penicillinases that are 
susceptible to p-lactamase inhibitors. The TEM-1 and SHV-1 P-lactamases, Group 2b, 
are the P-lactamases usually found in E. coli and K. pneumoniae that confer resistance 
to penicillins (ampicillin and piperacillin) [Bush et al., 1995]. Ambler Class B 
enzymes (Bush Group 3) are MBLs that use one of two zinc (Zn2+) atoms for 
inactivating penicillins and cephalosporins. In bacteria, MBLs confer resistance to 
carbapenems, cephalosporins and penicillins. Bacteria possessing MBLs are among 
the most resistant phenotypes encountered by clinicians. MBLs are inhibited by 
chelating agents (EDTA), but not by clavulanic acid or sulfones. The bla genes 
encoding MBLs are found on a variety of genetic elements (chromosome, plasmid, 
integrons, etc.) [Walsh et aJ., 2005]. Clinically important MBLs that are widespread 
are the IMF-type and VlM-type oi P. aeruginosa. Nearly 20% of imipenem-resistant 
P. aeruginosa strains possess a MBL. Ambler class C enzymes (Bush Group 1) 
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Table 1.2. B-Iactamase classification system 
Ambler Classification System 
Class A Penicillinases 
Class B Metallo-beta-lactamases 
Class C Cephalosporinases 
Class D Oxacillinases 
TEMs,SHVs,PCl, CTX-Ms, SME-
1,EPC-1 
IMP-1,VIM-1, CerA 
AmpCs,CMY-2,ACT-l 
OXA-I 
Bush-Jacoby-Medeiros Classification System 
Groupl Cephalosporinases, hydrolyz extended spectrum AmpCs, CMY-2,ACT-1,MIR-1 
cephalosporinases, Clavulanic acid resistant. 
Group2 All clavulanic acid susceptible, 
2a Penicillinase, 
2b broad spectrum penicillinase. 
PC-1 from S. aureus 
TEM-l,SHV-l,TEM-2 
2be ESBLs, SHV-2, TEM-10, CTX-Ms 
2br inhibitor resistant, 
2c Carbenicillin hydrolyzing, 
2d Oxacillin hydrolyzing, 
2e Cephalosporinases inhibited by clavulanate, 
2f Carbapenemases, 
Groups metallo-B-lactamases, Hydrolyze imipenem, 
inhibited by EDTA, resistant to clavualnate 
TEMs, IRTs, TEM-30, TEM-31 
PSE-1 
OXA-1,OXA-10, 
FEC-1 
KPC-1, SME-1 
IMP-l,VIM-l,Ccr-A 
Group4 Miscellaneous 
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include the chromosomal ly encoded AmpC type p-lactamses found in Citrobacter 
freundii, Enterobacter aerogenes and Enterobacter cloacae, Morganella morganii, P. 
aeruginosa and Serratia marcescens. Bacteria possessing AmpC p-lactamases are 
resistant to penicillins, P-lactamase inhibitors, cefoxitin, cefotetan, ceft^idime, 
ceftriaxone, and cefotaxime. Aztreonam and cefepime are usually more active against 
bacteria possessing class C P-lactamases. Historically, it was thought that ampC genes 
encoding class C P-lactamases were located exclusively on the chromosome but, 
within the last 17 years, an increasing number of ampC genes have been found on 
plasmids [Walther-Rasmussen et al., 2002]. These have mostly been acquired by 
AmpC-deficient pathogenic bacteria, which consequently are supplied with new and 
additional resistance phenotypes. Ambler classD enzymes (Bush group 2f) are serine 
P-lactamases that are able to hydrolyze oxacillin (hence oxacillinases or OXA P-
lactamases). The OXA enzymes of Acinetobacter baumannii and P. aeruginosa 
represent the most structurally diverse and rapidly growing group of p-lactamases 
[Brown et al., 2006, Walther-Rasmussen et al., 2006]. Depending on the OXA 
enzyme, these P-lactamases confer resistance to penicillins, cephalosporins, extended 
spectrum cephalosporins (OXA-type ESBLs) or carbapenems (OXA-type 
carbapenemases). OXA enzymes are relatively resistant to clavulanic acid 
inactivation, but are inhibited by sodium chloride [Naas et al., 1998, Poirel et al., 
2002]. 
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1.7.1 p-Lactamases implicated in resistance to p-lactam antibiotics used in 
urinary tract infections 
TEM-1, TEM-2 and SHV-1 are widespread enzymes that attack the narrow 
spectrum cephalosporins, cefamandole and cefoperazone and most of the penicillins. 
The name "TEM" is a contraction of Temoniera, the name of the patient from whom 
resistant bacteria were isolated, whereas SHV is a contraction of sulfhydryl variable; a 
description of the biochemical properties of this P- lactamase (Heritage et al., 1999). 
Epidemiological studies have shown the plasmid-mediated enzymes TEM-1, TEM-2 
and SHV-1 to be the most commonly encountered with TEM-1 predominant and 
responsible for 90% of ampicillin resistance in E. coli (Baker, 1999). The degree of 
resistance depends on the amount of TEM and SHV enzymes, which can vary 150-
fold among isolates, reflecting gene dosage and promoter efficiency (Reguera et al., 
1991; Heritage et al., 1999). These enzymes can be distinguished by biochemical 
criteria (substrate profiles, kinetic properties and reaction with inhibitors), physical 
properties (molecular size and isoelectric point), or by genetic criteria, such as 
inducibility and location of their genes on plasmids or on the chromosome (Philippon 
et al., 1989; Jacoby, 1994; Livermore & Williams, 1996). Within the bacterial cell, p-
lactamases contribute to antibiotic resistance in several ways. In E. coli (TEM-1 
producers) the P-lactamases remain localised in the periplasmic space and can destroy 
antibiotic molecules as they make their way through the outer membrane. 
Consequently, high level of resistance occurs within a single bacterial cell (Medeiros, 
1984; Zhou et al., 1994). Several parameters contribute to the level of antibiotic 
resistance mediated by a particular p- Lactamase in a population of bacteria. These 
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include rate of hydrolysis (Vmax), affinity for the antibiotic (Km), and the amount of 
P-lactamase produced (Pitout et al., 1998). 
By mid-1980s, resistance to expanded-spectrum cephalosporins had appeared in 
clinically significant Gram-negative bacteria, caused by the production of P-
lactamases. Among the first of the extended-spectrum P-lactamases to cause 
significant clinical problems, were mutants derived from SHV-1 or TEM-1 P-
lactamases. The genes encoding these mutants are present on mobile genetic elements, 
facilitating their spread in nosocomial pathogens (Heritage et al., 1999). 
(a) TEM-1 
TEM-1 is the most common plasmid encoded p-lactamase and was first recognized in 
E. coli in 1965 (Bryan & Godfrey, 1991; Ho et al., 1998). It has since spread to 20 -
60% of isolates oi Enterobacteriaceae, with varying frequency in species and location. 
Expression of TEM-1 is constitutive but the amount varies amongst strains. Low level 
TEM-1 causes resistance to ampicillin, amoxicillin and ticarcillin, while higher levels 
can result in resistance to piperacillin, mezlocillin, cephalothin, cefamandole and 
cefoperazone (Livermore, 1993). 
(b) SHV-1 
SHV-1 is a narrow spectrum P-lactamase with activity against penicillins. It was first 
described as a chromosomally encoded P-lactamase in Klebsiella (Heritage, 1999). It 
is classified in the Bush group 2b enzymes (Sanders & Sanders, 1992) and is encoded 
by blaSHV-1 gene, commonly encountered in clinical isolates on Self-transmissible 
plasmids. The amount of enzyme produced and expressed vary more than one hundred 
fold amongst strains, depending on the number of plasmid copies per organism, the 
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efficiency of the promoter and the degree of gene amplification (Jacoby & Carreras, 
1990; Abdel-Rahman & Keams, 1998; Petrosino et al., 1998). 
(c) Extended spectrum beta-lactamases (ESBLs) 
Members of the family Enterobacteriaceae commonly express plasmid-encoded P-
lactamases (e.g., TEM-1, TEM-2, and SHV-1) which confer resistance to penicillin 
but not to expanded-spectrum cephalosporins [Harbak; 2007]. In the mid-1980s a new 
group of enzymes, the extended-spectrum P-lactamases (ESBLs), was detected. 
ESBLs are beta-lactamases that hydrolyze extended-spectrum cephalosporins with an 
oxyimino side chain, e.g., CTX-M [http://en.wikipedia.org/wiki/Beta-Lactamase]. 
These cephalosporins include cefotaxime, ceftriaxone, and ceftazidime, as well as the 
oxyimino-monobactam aztreonam. ESBLs confer resistance to expanded spectrum 
cephalosporins (e.g. ceftriaxime, cefotaxime, and ceftazidime), aztreonam, and related 
oxyimino-beta lactamas [http://en.wikipedia.org/wiki/Beta-Lactamase; Rossolini et al., 
2006]. Typically, they drive from genes for TEM-1, TEM-2, or SHV-1 by mutations 
that alter the amino acid composition aroimd the active site of these P-lactamases. This 
extends the spectrum of P-lactam antibiotics susceptible to hydrolysis by these 
enzymes [Harbak; 2007; http://en.wikipedia.org/wiki/Beta-lactamase]. The ESBLs are 
frequently plasmid encoded. Plasmids responsible for ESBL production frequently 
carry genes encoding resistance to other drug classes (for example, aminoglycosides) 
[Bradford; 2001]. Therefore, antibiotic options in the treatment of ESBL-producing 
organisms are extremely limited. Carbapenems are the treatment of choice for serious 
infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have 
recently been reported [Bradford; 2001; Rossolini et al., 2006]. ESBLproducing 
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organisms may appear susceptible to some extended-spectrum cephalosporins. 
However, treatment which such antibiotics have been associated with high failure 
rates [http://en.wikipedia.org/wiki/Beta-Lactamase] 
(d) CTX-M-beta-lactamases 
In gram-negative pathogens, beta-lactamase production remains the most important 
contributing factor to beta-lactam resistance [Medeiros; 1991]. Penicilh'ns, 
cephalosporins, monobactams and carbapenems can all be hydrolyzed by multiple 
members of the beta-lactamase family of enzymes, which results in microbiologically 
ineffective compounds [Bush et al., 1998]. Although numerous new beta-lactams have 
been developed during the past 40 years in attempts to circumvent the activity of beta-
lactamases, it appears that the prime result has been the selection of more diverse and 
potentially more deleterious beta-lactamases. 
CTX-M is a recently described family of the extended-spectrum beta-lactamases 
[Tzouvelekis et al., 2000]. The name CTX reflects the potent hydrolytic activity of 
these beta-lactamases against cefotaxime [Bonnet; 2004]. These enzymes hydrolyze 
cephalothin better than benzylpenicillin and they preferentially hydrolyze cefotaxime 
over ceftazidime. They are inhibited better by the beta-lactamase inhibitor tazobactam 
than by sulbactam and clavulanate [Bush et al., 1993]. Rather than arising by 
mutation, they represent examples of plasmid acquisition of beta-lactamase genes that 
are normally foimd on the chromosome of Kluyvera species [Humeniuk et al., 2002]. 
CTX-M beta-lactamases were predominantly found in three geographic regions: South 
America, the Far East and Eastern Europe [Tzouvelekis et al., 2000; Baraniak et al., 
2002; Cao et al., 2002; Radice et al., 2002]. However, in recent years, CTX-M type 
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beta-lactamases have been reported in Western Europe, North America, China, Japan 
and India [Babini et al., 2000; Karim et al., 2001; Moland et al., 2003; Wang et al., 
2003; Yamasaki et al., 2003]. CTX-M type beta-lactamases may be the most frequent 
type of ESBLs worldwide. The number of CTX-M type beta-lactamases is rapidly 
expanding. More than 40 CTX-M variants are currently known [Tzouvelekis et al., 
2000]. They have been found in different Enterobacteriaceae including Salmonella 
spp [Bradford et al., 1998]. 
CTX-M enzymes can be sub classified by amino acid sequence similarities 
[Bonnet et al., 2000]. The phylogenetic study reveals five major groups of acquired 
CTX-M enzymes, (i) The CTX-M-1 group includes six plasmid-mediated enzymes 
(CTX-M-1, CTX-M-3, CTX-M-10, CTX-M-12, CTX-M-15, and FEC-1) [Matsumoto 
et al., 1988; Barthelemy et al., 1992; Gniadkowski et al., 1998; Karim et al., 2001; 
Kariuki et al., 2001; Oliver et al., 2001] and the unpublished enzymes CTX-M-22, 
CTX-M-23, and CTX-M-28 (Gene Bank accession numbers AY080894, AF488377, 
and AJ549244, respectively), (ii) The CTX-M-2 group includes eight plasmid-
mediated CTX-M enzymes (CTX-M-2, CTX-M-4, CTX-M-4L, CTX-M-5, CTX-M-6, 
CTX-M-7, CTX-M-20, and Toho-1) [Ishii et al., 1995; Bauemfeind et al., 1996; 
Bradford et al., 1998; Gazouli et al., 1998; Gazouli et al., 1998; Tassios et al., 1999; 
Saladin et al., 2002]. (iii) The CTX-M-8 group includes one plasmid-mediated 
member [Bonnet et al., 2000]. (iv) The CTX-M-9 group includes nine plasmid-
mediated enzymes (CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16, CTX-M-17, 
CTX-M-19, CTX-M-21, CTX-M-27, and Toho-2) [Ma et al., 1998; Labia; 1999; 
Sabate et al., 2000; Bonnet et al., 2001; Pai et al., 2001; Poirel et al., 2001; Cao et al.. 
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2002; Chanawong et al., 2002; Saladin et al., 2002; Bonnet et al., 2003] and two 
unpublished enzymes (CTX-M-24[Gene Bank accession number AY 143430] and 
CTX-M corresponding to Gene Bank accession number JP0074). (v) The CTX-M-25 
group includes the CTX-M-25 and CTX-M-26 enzymes (Gene Bank accession 
numbers AY 157676 and AF518567, respectively). 
1.8 Objectives of the study 
In view of the present background we initiated our study with the following 
objectives: 
1. To determine the distribution and antibiotic susceptibility patterns of bacterial 
strains isolated from patients with community acquired urinary tract infections 
(UTIs) at Aligarh hospital in India as well as identification of ESBL producers 
in the population of different uropathogens. 
2. To investigate the role of integrons as vehicles for antibiotic resistance genes. 
3. To detect which transferable extended spectrum beta-lactamase circulated in 
the community. 
4. To study role of horizontal gene transfer in multidrug resistant E. coli strains. 
5. To investigate and identify the outbreak strain among ESBLs producing E. coli 
strains by molecular genotyping. 
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2.1. Materials 
Materials used during the study were listed below 
2.1.1. Antibiotics 
The number of antibiotic discs used to carry out the study is listed below. All 
the antibiotic discs were purchased from Hi-Media, Pvt. Ltd, Mumbai, India. 
Amikacin 
Amoxycillin 
Ampicillin 
Amoxyclav 
Aztreonem 
Cephalothin 
Cefuroxime 
Cefazolin 
Cephotaxime 
Ceftazidime 
Ceftriaxone 
Cephopodoxime 
Cephoxitin 
Cefepime 
Chloramphenicol 
Ciprofloxacin 
Clindamycin 
Co-trimoxazole 
Ak 
Am 
A 
Ac 
Ao 
Ch 
Cu 
Cz 
Ce 
Ca 
Ci 
Cep 
Cn 
Cpm 
C 
Cf 
Cd 
Co 
30 pig 
30 ^g 
10 Mg 
20/10 ng 
10 ng 
30 ng 
30 ^g 
30 ng 
30 Mg 
30 Mg 
30 Mg 
10 ng 
30 Mg 
30 Mg 
30 ^g 
5Mg 
2^g 
12.5/12.5 i^g 
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Erythromycin 
Fusidic acid 
Gentamicin 
Imipenem 
Nitrofurantoin 
Nalidixic acid 
Norfloxacin 
Penicillin-G 
Piperacillin 
Tetracyclin 
Tobramycin 
E 
Fc 
G 
I 
Nf 
Na 
Nx 
P 
Pc 
T 
Tb 
2.1.2. Culture media 
30 ng 
10 Mg 
10 Mg 
10 ^g 
30 ^g 
30 fig 
30 fig 
10 units 
100 units 
30 Mg 
30 ng 
List of the culture media used for the isolation and identification of the organism 
was purchased from Hi-Media, Pvt. Ltd. Mumbai, India. 
Agar agar 
Brain-Heart Infusion Broth. 
EMB-Broth 
Luria-Bertani broth 
Mac-Conkey agar 
Mueller-Hinton agar 
Mueller-Hinton broth 
Nutrient agar 
Nutrient broth 
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Tryptic Soy Broth 
2.1.3. Chemicals and reagents used: 
Acetone 
Agarose 
Agarose PFGE grade 
Ammonium chloride 
Ammonium oxalate 
Ammonium persulphate 
Barium chloride 
Benzyl penicillin 
Boric acid 
Bromocresol purple 
Bromophenol blue 
CaCl2 
Chloroform 
Cotton swab 
Crystal violet 
DNA 
DNA ladder (100 bp) 
DNA ladder (lOObp) 
DNA ladder (Ikb) 
dNTPs 
EDTA 
SRL, India 
SRL, India 
Sigma, USA 
SRL, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Genei-Bangalore, India 
Fermentas, USA 
Genei-Bangalore, India 
Genei-Bangalore, India 
SRL, India 
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Ethanol 
Ethedium bromide 
Glacial acetic acid 
Glycerol 
Hydrochloric acid 
Hydrogen peroxide 
Iodine crystals 
Isoamyl alcohol 
KCI 
KOH 
Lysostaphin 
Lysozyme 
MgCl2 
Na2HP04 
NaH2P04.H2O 
NaOH 
Oxacillin salt 
Phenol 
Phenol red 
Potassium iodide 
Proteinase K 
PCR buffer 
RNase 
E. Merck, India 
Sigma, USA 
E. Merck, India 
SRL, India 
SRL, India 
SRL, India 
Hi-Media, India 
SRL, India 
SRL, India 
Hi-Media, India 
Sigma, USA 
Sigma, USA 
SRL, India 
Hi-Media, India 
Hi-Media, India 
SRL, India 
Ranbaxy, India 
Sigma, USA 
Hi-Media, India 
Hi-Media, India 
Sigma, USA 
Sigma, USA 
Sigma, USA 
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Safranine 
SDS 
Sodium acetate 
Sodium bicarbonate 
Sodium chloride 
Xbal 
Tris-HCl 
Taq Polymerase 
Xylene cyanol 
Gel extraction Kit 
Sigma, USA 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Fermentas, 
E. Merck, India 
Sigma, USA 
Bio-Rad, USA 
Qiagen, USA 
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2.2. Methods 
2.2.1. Bacterial isolates 
The study was conducted on patients attending outpatient clinics at the 
J.N.M.C.H, A.M.U., Aligarh between August 2004 and July 2005. Freshly voided 
midstream specimens of urine (n= 920) were submitted to the clinical microbiology 
laboratory of J.N.M.C.H, Aligarh for processing. Semi quantitative urine culture 
using a calibrated loop was used to inoculate blood agar and Mac-Conkey agar 
plates [Claridge et al., 1987]. Following the recommendations of Kass [Kass, 1957] 
in distinguishing genuine infection from contamination, significant monomicrobic 
bacteriuria was defined as culture of a single bacterial species from the urine sample 
at a concentration of > 105 cfu/ml. Only a single positive culture per patient was 
included in the analysis. The significant pathogens were identified by standard 
biochemical procedures [Baron et al., 1994]. UTI patients included in this study 
were classified as young and middle aged (20-49 years), pediatrics (New bom to 19 
years) and elderly patients (50-80 years). Isolates were screened for antibiotic 
resistance by routine disc susceptibility and those reported to be resistant to more 
than one drug were stored at -70°C in a solution containing 7% glucose, 7% peptone 
and 30% glycerol. 
2.2.2. Bacterial identification 
Each sample after overnight incubation at 37°C was transferred to selective mecUa 
Set of biochemical tests (Gram staining, motility test, c )^sule stainii^ carbohydrate 
fermentation test. Indole test, methyl red test, Voges Proskaeur test, citrate test, 
urease test, oxidase test and nitratase test) was used for all the isolates. E. coli, was 
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grown on Eosin Methylene Blue (EMB) agar and also confirmed by Hi E. colF^ 
Identification Kit (Hi Media). A typical E. coli gave colonies with metallic sheen on 
EMB agar. Moreover E. coli isolates gave Indole and Methyl Red test as positive; and 
Voges-proskauer, Citrate, and Urease test as negative. On Mac Conkey Agar, E coli 
appeared as non-capsulated, motile, circular, oxivex, and smootfi colonies. Klebsiella 
spp. was confirmed by growing on Hi Crome Klebsiella Selection Agar Base with 
Klebsiella selective supplement. It appeared as small, dark brown colonies. On Mac 
Conkey agar Klebsiella appeared as large pink colonies, very mucoid, capsulated and 
non-motile. A typical Klebsiella pneumoniae gives Indole and Methyl Red test as 
negative; and Voges- proskauer, Citrate, and Urease test as positive. 
2.2.3. Antimicrobial susceptibility testing 
2.2.3.1. Disc diffusion test 
2.2.3.1.1. Storage of antimicrobial discs 
Cartridges containing commercially prepared paper disks specifically for 
susceptibility testing are generally packaged to ensure appropriate anhydrous 
conditions. Discs were stored at 8°C or below or froze at -14°C or below, until needed. 
The unopened disk containers were removed from the refrigerator 1 to 2 hr before use 
to equilibrate these to room temperature. Once a cartridge of discs has been removed 
from its sealed package, it was placed in tightly sealed, desiccated box. 
2.2.3.1.2. Turbidity standard for inoculum preparation 
To standardize the inoculum density for a susceptibility test, the BaS04 turbidity 
standard equivalent to a 0.5 McFarland standard was used (Andrews et al., 2004). 
BaS04 0.5 McFarland standard was prepared as follows; 
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A 0.5 ml aliquot of 0.048 M BaCb (1.175% wlv BaCl2.2H20) was added to 99 
ml of 0.18 M H2SO4 (1 % v/v) with constant stirring. The correct density of the 0.5 
McFarland standard was verified by determination of absorbance at 625 nm with a 1 
cm path length and was found to be 0.08 to 0.10. The turbidity suspension was 
transferred in 4 to 6 ml aliquots into screw-cap tubes of the same size or those used in 
growing or diluting the bacterial inoculum. The tubes were tightly sealed and stored in 
the dark at room temperature. The turbidity standard was vigorously agitated on a 
mechanical vortex mixer before each use and inspected for a uniformly turbid 
appearance. Standards may be stored for up to six months after which time they should 
be discarded. 
2.2.3.1.3. Inoculum preparation 
Three to five isolated colonies of same morphological types were selected from 
an agar plate culture. The top of each colony was touched with a loop and the growth 
was transferred into a tube containing 5 ml of a suitable medium such as tryptic soy 
broth. The broth culture was incubated at 37°C until it achieved or exceeded the 
turbidity of the 0.5 McFarland standard (usually 2 to 6 hours). This results in a 
suspension containing approximately 1 to 2x10* CPU/ml. The turbidity of the actively 
growing broth culture was adjusted with sterile saline or broth to obtain turbidity 
optically comparable to that of the 0.5 McFarland standard. This results in a 
suspension containing approximately 1.5x10* CFU/ml. 
2.2.3.1.4. Inoculation of test plates 
Optimally, within 15 min after adjusting the turbidity of the inoculum 
suspension, a sterile cotton swab was dipped into the adjusted suspension. The swab 
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was rotated several times and pressed firmly on the inside wall of the tube above the 
fluid level to remove excess inoculum from the swab. The dried surface of a Mueller-
Hinton agar plate was inoculated by streaking the swab over the entire sterile agar 
surface. This procedure was repeated by streaking two more times, rotating the plate 
approximately 60° each time to ensure an even distribution of inoculum. As, a final 
step the rim of the jar was swabbed. The lid was kept ajar (slightly open) for 3 to 5 
minutes to allow for any excess surface moisture to be absorbed before applying the 
drug impregnated discs. 
2.2.3.1.5. Application of discs to inoculated agar plates 
Within 15 min after the inoculation of plates, the antibiotic disks were applied so 
that diffusion and growth could proceed simultaneously. The discs were applied with 
the help of sterile forceps. Four discs were applied on each agar plate arranged at least 
20 mm from the edge of the plate and apart from each other by a distance of 15 to 20 
mm. The plates were inverted and placed in an incubator set at 37°C within 15 
minutes after the discs were applied. The incubation period was maintained for 18 to 
24 hrs. 
2.2.3.1.6. Reading plates and interpreting results 
After 18 to 24 hrs of incubation, each plate was examined. The zones of inhibition 
were uniformly circular due to a confluent lawn of growth. The diameters of the zones 
of complete inhibition were measured, including the diameter of the disc. The zones 
were measured to the nearest whole millimeter, using a ruler, which was held on the 
back of the inverted petri plate. The petri plates were held a few inches above a black, 
non reflecting background and illuminated with reflecting light. Discrete colonies 
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growing within a clear zone of inhibition were subcultured, re-identified, and retested. 
The sizes of the zones of inhibition were interpreted by referring to standard tables in 
NCCLS documents (NCCLS, 7*^  Edt. 2000). E. coli ATCC 25922, S. aureus ATCC 
29213, P. aeruginosa ATCC 27853, E. faecalis ATCC 29212, E. coli BCC 2132 
(ESBL producer), and E. coli ATCC 35218 (non-ESBL producer) were used as quality 
control strains. Interpretative criteria for each antimicrobial tested were those 
recommended by the CLSI-2000 [CLSI, 2000]. 
2.2.4. ESBL detection by CLSI phenotypic method 
Production of ESBLs was studied by the double disc synergy test as described by 
Jarlier et al., (1988). Isolates were inoculated on MH-agar plates. Discs containing 
respectively ceftazidime (30^g), cefazolin (30ng), cefoxitin (30fig) and aztreonam 
were placed 25 mm (centre to centre of the discs), from a disc containing amoxicillin/ 
clavulanic acid (10/20^g). After overnight incubation at 37°C, the diameters of 
inhibition zones around the antibiotic discs were measured using a emtibiotic inhibition 
zone reader scale. A clear extension of the edges of the inhibition zone of any of the 
antibiotics towards the disc containing clavulanic acid, was regarded as a phenotypic 
confirmation of the presence of ESBL (Jarlier et al., 1988; Acar and Goldstein, 1996; 
Collee et al., 1996). Susceptibility test results were interpreted according to the criteria 
established by the CLSI [CLSI, 2001]. A > 5-mm increase in the zone of diameter of 
third generation cephalosporins, tested in combination with amoxyclav versus its zone 
when tested alone was considered indicative of ESBL production. E. coli ATCC 
25922 and K. pneumoniae 700603 were used as control strains. 
59 
ChQptizr-2 
2.2.5. Statistical analysis 
To analyze the data it was reported in the form of diameter of inhibition zone 
during susceptibility testing of all bacterial isolates by disc diffusion test against 
different classes of antimicrobial agents. One-way ANOVA was performed to check 
the significant difference among the different groups. A difference was considered 
significant if the probability that chance would explain the results was reduced to less 
than 5% (p<0.05). The normality and homogeneity was also checked. 
2.2.6. Transfer of resistance through conjugation 
To determine if the genes are located on the chromosome or on a plasmid, 
conjugation was done by using selected resistant strains as donors and Escherichia 
coli (EJ-53) (resistant to 250 |ig of sodium azide), as selective recipient in all 
conjugation studies. Multi-drug resistant donor strains and recipient strain EJ-53 were 
inoculated into nutrient broth separately and incubated at 37°C until the cells reached 
logarithmic growth phase. 200 ^l of recipient and 50^1 of donor were then added to 5 
ml of fresh nutrient broth and incubated overnight at 37°C. A loop-ful of the mixture 
was then spread on the surface of MacConkey agar containing ampicillin (25 fig/ml) 
plus sodium azide (250^g/ml) as selective antibiotics. The plates were incubated 
overnight at 37°C. Colonies of E. coli (EJ-53) that grew on the sodium azide 
/ampicillin selective plates and again on subculture on ampicillin plates were regarded 
as trans-conjugants. 
2.2.7. Plasmid DNA preparation 
The plasmid DNAs were extracted by QIAprep Spin Miniprep Kit. In brief, one 
colony from each strain was inoculated in 5 ml of LB (Luria-Bertani broth) containing 
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a suitable concentration of antibiotic for selection, for 18 hours at 37 °C. The 
overnight cultures were centrifuged at 8,000 rpm for 15 minutes at 4 °C to pellet the 
cells. The pellets were resuspended in 250 ^l of Buffer PI (50 mM TRIS-HCl, 10 mM 
EDTA, pH 8.0 containing 100 ^g/ml RNase A). 250 jil of Buffer P2 [200 mM NaOH, 
1% SDS (w/v)] was added to the samples, mixed thoroughly by vigorously inverting 
4-6 times and incubated at room temperature for 5 minutes. Then 350 nl of chilled 
Buffer N3 ( 3.0 M potassium acetate, pH 5.5) was added to the cell lysates, mixed 
thoroughly by vigorously inverting 4-6 times and incubated on ice for 15 minutes. The 
samples were centrifuged for 10 minutes at 13,000 rpm at 4 °C. The supematants 
containing the plasmids were applied to the QIAprep spin columns. The columns were 
washed twice with 0.75 ml of Buffer PE [70% ethanol]. Discard the flow-through, and 
centrifuge for an additional 1 min to remove residual wash buffer. The plasmid DNAs 
were eluted with 50 nl of Buffer EB [10 mM Tris-Cl, pH 8.5] or distilled water. 
2.2.8. Total genomic DNA preparation 
Total DNAs from strains containing studied plasmids were extracted by QIAamp 
DNA Mini Kit, by the following procedure: one colony from each strain was 
inoculated in 5 ml of LB (Luria-Bertani broth) containing a suitable concentration of 
antibiotic for selection, for 18 hours at 37 °C. 1 ml of overnight cultures were 
transferred in a 1.5 ml micro-centrifuge tube and centrifuged at 7500 rpm for 10 
minutes to pellet the cells. To lyse the cells, the pellets were resuspended in 180 p.1 of 
Buffer ATL, 20 ^1 of proteinase K was added, mix by vortexing, and incubated at 56 
°C until the cells were completely lysed (lysis is usually complete in 1-3 hours). 
Vortex occasionally during incubation to disperse the sample. 4 fj,l of RNase Solution 
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(100 mg/ml) were added to cell lysates, mix by pulse vortexing for 15s, and incubated 
at 37 °C for 2 minutes. 200 \i.\ Buffer AL was added to the RNase-treated cell lysates, 
vortexed vigorously for 15s and incubated at 70 °C for 10 minutes. Then 200 1^ 
ethanol (96-100%) was added to the sample, and mix by pulse vortexing. This nixture 
was then applied to the QIAamp Mini spin column with 2 ml collection tube and 
centrifuge at 8000 rpm for 5 minutes. Place the QIAamp Mini spin column in a clean 2 
ml collection tube, and discard the tube containing the filtrate. 500 nl Buffer AWl was 
added and^centrifuge at 8000 rpm for 2 minutes. The columns were washed again with 
500 ^l Buffer AW2 and centrifuge at 8000 rpm for 3 minutes. Discard the flow-
through, and centrifuge for an additional 1 min to remove residual wash buffer. The 
genomic DNAs were eluted with 200 ^1 of Buffer AE [10 mM Tris-Cl, pH 8.5] or 
distilled water. 
2.2.9. PCR amplification 
Isolates positive for ESBL production were subjected to polymerase chain reaction 
(PCR) amplification using primers designed for the detection of integrons, blaTEM, 
blaSHV and blaCTX-M genes. These samples were screened by PCR with 11 sets of 
primers for the detection of integrons; TEM-and SHV- derived extended spectrum 
beta-lactamases; CTX-M-1, CTX-M-2, CTX-M-3, CTX-M-8, CTX-M-9 and CTX-M-
15 beta-lactamases (Table 2.1). The sets of PCR primers and the amplification 
conditions used to detect beta-lactamases and integrons have been reported previously 
(Levesque et al, 1995, Mugnaoli et al, 2006,Kim et al, 2005, and Shibata et al, 2006.). 
The PCR amplicons were electrophoresed on a 1% agarose gel. Oligonucleotide 
primers used for PCR amplification are listed in table (2.1). Standard PCRs were 
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carried out in 50 nL volumes containing 5 nL of 10 x PCR buffer (100 mM Tris-HCl 
(pH 8.8), 500 mM KCl, 15 mM MgCl 2, 1% Triton X-100), 5 ^L of 10 x 
deoxynucleotide triphosphate mix (2 mM each dATP, dCTP, dGTP and dTTP) 
(Sigma,USA.), 2 nL of each primer stock solution (25 pmol/^L), 35 i^L sterile distilled 
water and 1 \iL Taq- polymerase (1.5 U/nL diluted solution) (Sigma,USA), and 2-5 
^L (lOOng-l^g) of template DNA. Amplification was performed in a thermocycler 
(Applied Biosystem, veriti, 96-well thermal cycler 9902, Connecticut, USA). 
2.2.9.1. Agarose gel electrophoresis 
PCR products (25 \x\) were mixed with 2-8 ^l of 10 x TAE buffer and 1-4 ^l of 
bromophenol blue (0.25%). PCR mixtures were applied to 1-1.5% agarose gels 
(Sigma, USA) and products separated by electrophoresis for 2-4 h at 90 V using 1 x 
TAE running buffer (4.84 g/L Tris, 0.37 g/L EDTA, pH 8). The products were 
visualized by placing gel on a UV transilluminator (254-360 nm) and photographed 
using Gel Documentation (Bio-Rad Laboratories). A 100 bp DNA ladder, Ikb DNA 
ladder and DNA mix ruler were included in this study. 
2.2.9.2. DNA extraction 
PCR products (100 |il) were separated by agarose gel electrophoresis (section 
2.4.2) on 1% gels and bands of predicted sizes cut from the gels with minimum 
exposure to UV illumination. The DNA was extracted from the gel slices using a DNA 
extraction kit (Qiagen, USA) by incubation in sodium perchlorate (for extracting 
fragments <500 bp) or sodium iodide (for fragments >500 bp) at 55°C for 5 min. 
Resin (15 i^l) was then added and the samples incubated at room temperature for 1 
min. After centrifiigation at 16 000 x g for 30 sec, the pellet was resuspended in 1 ml 
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Table 2.1. Primers used in the study. 
Primer set 
Annealing temperature 
(°C)/Accession No. 
SHV-A: 5'-CAC TCA AGG ATG TAT TGT G-3' 
SHV-B: 5' -TTA GCG TTG CCA GTG CTC G-3' 
58/AY223863 
TEM-S: 5'-ATAAAATTCTTGAAGACGAAA-3' 
TEM-AS: 5'-GACAGTTACCAATGCTTAATC-3' 
55/AB103506 
5'CS: 5' -GGCATCCAAGCAGCAAG-3' 
3' CS: 5' -AAGCAGACTTGACCTGA-3' 
55/M73819 
Int I -F: 5'-CTACCTCTCACTAGTGAGGGGCGG-3' 
Intl-B:5'-GGGCAGCAGCGAAGTCGAGGC-3' 
55/U12338 
Sull: 5'-ATGGTGACGGTGTTCGGCAT3' 
Sull: 5'-CTAGGCATGATCTAACCCTC 3' 
58 
CTX-MUl: 5'-ATGTGCAGYACCAGTAARGT-3' 
CTX-MU2: 5'-TGGGTRAARTARGTSACCAGA-3' 
50/ JCM, 41:4264-4269, 2003. 
CTX-M-l-S:5'-CGTCACGCTGTTGTTAGGAA-3' 
CTX-M-l-AS:5'-ACGGCTTTCTGCCTTAGGTT-3' 
50/AJ632119.1 
CT-M-2-S:5-TTAATGATGACTCAGAGCATTC-3' 
CTX-M-2-AS:5'-GATACCTCGCTCCATTTATTG-3' 
50/X92507 
CTX-M3G-F:5'-GTTACAATGTGTGAGAAGCAG-3' 
CTX-MEG-B: 5'-ACGGAATGAGTTTCCCCCATT-3' 
50/JCM, 43:4183-4185, 2005. 
CTX-M-8-F: 5' -CGGATGATGCTAATGACAAC-3' 
CTX-M-8-R: 5'-GTCAGATTGCGAAGCGTC-3' 
50/AAC, FEB.2006, P-791-795. 
CTX-M-9-S:5'-TATTGGGAGTTTGAGATGGT-3' 
CTX-M-9-AS:5'-TCCTTCAACTCAGCAAAAGT-3' 
50/ AAC, FEB.2006, P-791-795. 
CTX-M-15F: 5'-AGAATAAGGAATCCCATGGTT-3' 
CTX-M-15R: 5'-ACCGTCGGTGACGATTTTAG-3' 
50/AAC, 2005, 49:477-478. 
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washing solution, followed by a 1:1 dilution with 99% ethanol. The sample was again 
centrifuged at top speed for 30 sec and the supernatant discarded. The pellet was 
incubated at 55°C (tube with open lid) until all the alcohol had evaporated. Sterile 
distilled H2O (10 nl) was added to the pellet after 1 min incubation at room 
temperature. After centrifugation for 30 s the supernatant containing the DNA was 
carefiilly removed to a clean tube. The final step was repeated to yield approximately 
20^1 of DNA sample. 
2.2.10. Genotyping using PFGE 
PFGE typing of clinical Escherichia coli strains isolated during the study was 
performed as described by Liu, et al. (1995). 
2.2.10.1. Preparation of agarose plugs and treatment with lysis buffer 
The test strains were grown in 5 ml nutrient broth. 200 ^1 of an overnight grown 
culture was taken in a sterile eppendorf tube and centrifuge at 10,000 rpm for 5 min 
and aspirated the supernatant. The pellet was resuspended in 200 (xl of EET buffer 
(100 mM EDTA, 10 mM EGTA, 10 mM Tris-Hcl, pH 8.0) and was adjusted to a 
concentration of lO'CFU/ml with a colorimeter. This bacterial suspension was 
equilibrated at 37°C in water bath for 10 minutes, mixed with an equal volume of 2% 
low-melting-point agarose and allowed to solidify an a 100 1^ plug mold (Bio-Rad 
Laboratories). This was done quickly and carefully to avoid the shearing of DNA and 
creation of bubbles in the tube or subsequently in the plug mold. The plug molds were 
kept on ice for 30 min for the agarose to set. For lysis, the DNA blocks were incubated 
overnight at 37°C in a 2ml lysis buffer (lOmM Tris-Hcl [pH 7.6], lOOmM EDTA, 100 
mM Nacl, 0.5% Brij58, 0.2% sodium deoxycholate, 0.5% sodium lauryl sarcosine. 
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and lysozyme [0.5mg/ml]). Following this step, the lysis buffer was replaced with 2ml 
of proteolysis buffer (1% sodium lauryl sarcosine, 0.5M EDTA [pH 9.5], and 500ng 
of proteinase K [Sigma Chemical Co., St. Louis, Mo] per ml), and this solution was 
incubated with gentle shaking at 56°C for 2 days, the proteolysis buffer was changed 
after 24 hr. To eliminate the lysed bacterial material and inactivate proteinase K 
activity, the DNA blocks were washed once for Ih at room temperature in 10ml of TE 
buffer (lOmM Tris-Hcl [pH7.5] and lOmM EDTA) and once for Ih at 37°C in TE 
buffer containing ImM phenylmethylsulfonyl fluoride (Sigma), To remove 
phenylmethylsulfonyl fluoride, the DNA blocks were washed once in 2ml of TE 
buffer at 4°C for Ih. The DNA blocks were washed once in 1ml of O.IXTE buffer at 
4°C for 30 min. to avoid the activity of restriction endonuclease being decreased by 
TE buffer. 
2.2.10.2. Restriction digestion with Xbal 
A slice of each block (3.5 by 5mm) was cut and washed in 100 |jil of Xbal reaction 
buffer (Fermentas) at 4°C for 30 min. Then, Xbal reaction buffer was replaced with 
100 ^1 of fresh reaction buffer containing 50U of the restriction endonuclease Xbal 
(Fermentas). The DNA blocks were incubated at 37 °C for 24h. 
2.2.10.3. Pulsed field gel electrophoresis 
After DNA digestion, the agarose plugs were incubated with 1 ml of TE buffer at 
37°C for 1 hr. The plugs were then loaded into 1.2% agarose gel in 0.5X TBE buffer. 
After loading the wells were sealed with 1.5% low melting point agarose. Restriction 
fragments of the DNA were separated by PFGE with a CHER-DRII apparatus (Bio-
Rad Laboratories) through 1.2% PFGE agarose (Sigma) at a field strength of 6V/cm 
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for 22 h at 14 °C, with the pulse time being increased from 5 to 20s. A lambda ladder 
(Sigma) was used as the molecular size marker. 
2.2.10.4. Staining and visualizing gel 
To stain the gel after a run, the gel was slid off the platform in to a 0.5^g/ml 
ethidium bromide solution in water and was let to be stained for 20-30 minutes. The 
gel was destained in distilled water for 1-2 hours. The DNA was visualized by placing 
gel on a UV transilluminator (254-360nm) and photographed using Gel 
Documentation (Bio-Rad Laboratories). 
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3.1. Introduction 
Community-acquired urinary tract infection (UTI) is one of the most common 
infectious diseases and a frequent cause of presentation for outpatient treatment. 
Worldwide, about 150 million people are diagnosed with UTI each year, costing the 
global economy in excess of 6 billion US dollars [Gonzalez et al., 1999]. UTI may 
involve only the lower urinary tract or may involve both the upper and lower tract. 
The term cystitis has been used to describe lower UTI, which is characterized by a 
syndrome involving dysuria, frequency, urgency and occasionally suprapubic 
tenderness. However, the presence of symptoms of lower tract without upper tract 
symptoms does not exclude upper tract infection, which is also often present [Sobel et 
al., 2000]. 
UTIs are often treated with different broad-spectrum antibiotics when one with a 
narrow spectrum of activity may be appropriate because of concerns about infection 
with resistant organisms. Fluoroquinolone are preferred as initial agents for empiric 
therapy of UTI in area where resistance is likely to be of concern [Schaeffer et al., 
2002]. This is because they have high bacteriological and clinical cure rates, as well as 
low rates of resistance, among most common uropathogens [Goldstein et al., 2000]. 
The extensive uses of antimicrobial agents have invariably resulted in the development 
of antibiotic resistance, which, in recent years, has become a major problem 
worldwide [Biswas et al., 2006]. Epidemiological studies to better manage infections 
such as UTIs generally involve surveys of isolates from a defined location or locations 
for the purpose of identifying common resistance profiles [Farrell et al., 2003; 
Kurutepe et al., 2005; Tumidge et al., 2002]. These studies attempt to survey 
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resistance to clinically important antibiotics generally or focus on particular families 
of antibiotics and the corresponding genes that encode resistance to them. Such 
surveys can lead to treatment strategies that make use of antibiotics to which strains 
are likely to be sensitive and can be useful in the short term for the development of 
detection and management strategies [Gupta et al., 2001; Tumidge et al., 2007]. The 
resistance pattern of community acquired UTI pathogens has not been studied 
extensively [Goldstein et al., 2000]. The etiology of UTI and the antibiotic resistance 
of uropathogenes have been changing over the past years, both in community and 
nosocomial infection [Gupta et al., 2002, and Tankhiwale et al., 2004]. However, there 
are not much information on etiology and resistance pattern of community acquired 
UTIs in India is available. This retrospective study was conducted to compare the 
frequency and drug resistance pattern in uropathogenes isolated from patients with 
community acquired UTIs in Aligarh, India as well as identification of ESBL producer 
strains among the uropathogens. This study is important for clinician in order to 
facilitate the empiric treatment of patients and management of patients with symptoms 
of UTIs. Moreover, the data would also help authorities to formulate antibiotic 
prescription policies. 
3.2. Experimental overview 
Urinary isolates from symptomatic UTI cases attending to the JN Medical 
College and hospital at Aligarh were identified by conventional biochemical methods 
by using Biochemical test kits from Hi-media laboratories, Mumbai, India. 
Antimicrobial susceptibility testing was performed by Kirby Bauer's disc diffusion 
method outlined in section 3.2. Isolates resistant to third generation cephalosporin 
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were tested for ESBL production by double disk synergy test method as discussed in 
section 3.3. 
3.3. Results 
Of the 920 urine samples processed 100 (10.86%) gave significant growth of 
pathogens. The patients were between new bom and 80 years of age. More cases of 
UTIs were recorded among young and middle age patients (20-49 years, 51.04%). 
Pediatric patients (new bom to 19 years) comprised 36.45% and elderly (50-80 years) 
constituted 16.66 % of the total number. More organisms were isolated from women 
(66.66 %) than from men (33.34 %). 
Age and gender wise data of prevalence of uropathogenes revealed that E. coli 
(87%) Klebsiella spp. (89%) Psneodomonas spp. (100%) and Acinetobacter spp. 
(67%) infection was found to be more prevalent among middle aged female candidates 
as shown in table 3.1. Moreover, none of the Psueodomonas and Acinetobacter spp. 
were found in pediatric patients (NB to 19 years) whereas Acinetobacter spp were not 
observed among elderly patients (50-80 years) in our study (table 3.1). 
Of the 100 significant isolates, gram-negative aerobic rods accounted for 92 % 
while gram-positive cocci accounted for the remaining 8 % of the total pathogens. The 
frequency and distribution of the different microorganisms is summarized in Table 
3.2. E. coli (61%), Klebsiella spp. (22%), Pseudomonas spp. (4.0%), Staphylococcus 
aureus (7.0%), Acinetobacter spp. (3.0%), Citrobacter spp. (2.0%) and E. faecalis 
(1.0%) were the most prevalent microorganisms in UTI patients. Frequency of UTIs 
was found more in elderly patients (51.04 %), principally women (66.66 %) than in 
pediatric patients 
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Table 3.1. Age and gender wise distribution of urinary tract infection (UTI) patients. 
Patient's age group (Years) No. of UTI Patients (%) Sex 
(Neonate to teenagers) 30 (31.25) 
(20-50) 50 (52.08) 
(50-80) 
16 (16.66) 
Total patients 96.00 
M (33.33%) 
F (66.6%) 
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Table 3.2. Frequency and distribution of urinary pathogens isolated from community 
acquired infection patients. 
Uropathogen Numbers 
61 
22 
07 
04 
03 
02 
01 
Percentage (%) 
61 
22 
07 
04 
03 
02 
01 
E.coli 
Klebsiella spp. 
S.aureus 
Pseudomonas spp. 
Acinetobacter spp. 
Citrobacter spp. 
E. faecalis 
-72 
Chaptizr-3 
The antimicrobial potency and spectaim for 27 selected antimicrobial agents of 
different classes against the five most frequent UTI pathogens are summarized in table 
3.3. Among the B-lactum antibiotics, imipenem had the widest coverage against E. coli 
isolates (100%), followed by amikacin (49%), and extended spectrum cephalosporins 
(15-45%). Moreover, a high potency of the fluoroquinolones against E. coli was 
observed. 
Our Klebsiella isolates showed high percent susceptibility against imipenem 
(88%) followed by amikacin and cephotaxime (59%) and ceftriaxone (53%). 
Nitrofurantoin, tetracycline, co-trimoxazole, and cefpodoxime were found to be hi^ly 
resistant (100%) against Pseudomonas isolates. Among the beta lactam antibiotics, 
imipenem had the widest coverage against gram-negative isolates (100%). This was 
followed by the amikacin, ciprofloxacin and norfloxacin (67%). 
Imipenem, amikacin, ciprofloxacin and norfloxacin showed highest percent 
susceptibility (100%) against Acinetobacter spp. in this study. Third and fourth 
generation cephalosporins were found to be more effective with significant percent 
susceptibility (67%) against Acinetobacter spp. Aminoglycosides and macrolides also 
had the same percent susceptibility (67%). Whereas, all Staphylococcus aureus 
isolates were found to be susceptible against imipenem, ceftriaxone and cephotaxime. 
The high resistance rate (60%) against cefpodoxime, nalidixic acid and aztreonem was 
also observed among these isolates. 
Age wise distribution of antibiotic resistance pattern revealed that 
uropathogens isolated from the patients of different age groups showed slight variation 
in percent resistance against different antibiotics. It was found that percent resistance 
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Table 3.3. Antimicrobial potency and spectrum for 27 selected antimicrobial agents tested against 
vntic* fwtinnant\v nnnttrrina TTTT n a f h n o p n c a n d *>/> F, .^RT. n r n H l l C t i n t l . 
Class of 
Antimicrobial 
agents 
l»*gen. 
Cephalosporins 
2"" gen. 
Cephalosporins 
3^ " gen. 
Cephalosporins 
4"" gen. 
Cephalosporins 
Aminoglycosides 
Penicillins 
Carbapenem 
Monobactum 
Macrolides 
Lincosamides 
Quinolones 
Fluroquinolones 
Phenicols 
Tetracycline 
Beta-lactum 
Inhibitors 
Others 
% ESBL producers 
Percent resistance (%) against antimicrobial agents for 
Antimicrobi 
al agents 
Cephalothin 
Cefazolin 
Cufuroxime 
Cephoxitin 
Cephotaxime 
Ceftazidime 
Ceftriaxone 
Cefpodoxime 
Cefepime 
Gentamicin 
Amikacin 
Tobramycin 
Ampicillin 
Penicillin-G 
Piperacillin 
Imipenem 
Aztreonam 
Erythromycin 
Clindamycin 
Nalidixic 
acid 
Ciprofloxacin 
Norfloxacin 
Chloram-
phenicol 
Tetracycline 
Amoxyclav 
Co-
trimoxazole 
Nitroftirantoi 
n 
34.42 
E. coli 
85 
71 
78 
69 
56 
65 
55 
85 
67 
64 
51 
73 
75 
87 
84 
0 
75 
89 
91 
87 
69 
69 
53 
76 
75 
76 
80 
27.3 
Kelebsiell 
aspp. 
71 
53 
53 
53 
41 
53 
47 
65 
53 
53 
35 
53 
76 
88 
82 
12 
59 
82 
94 
59 
47 
47 
35 
53 
53 
53 
16 
-
Pseudomo 
nas spp. 
67 
67 
100 
67 
67 
67 
67 
100 
61 
61 
33 
67 
100 
100 
67 
0 
67 
100 
100 
100 
33 
33 
100 
100 
100 
100 
100 
-
s. 
aureus 
20 
20 
40 
40 
0 
40 
0 
60 
20 
20 
20 
20 
20 
40 
40 
0 
60 
40 
20 
60 
40 
40 
40 
40 
40 
40 
20 
-
Acinetobact 
er spp. 
67 
67 
67 
67 
33 
33 
33 
67 
33 
33 
0 
33 
33 
67 
67 
0 
67 
61 
33 
67 
0 
0 
33 
33 
33 
33 
33 
-
Numbers of isolates are significant 
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against different generation of cephalosporin was found to be 60-80 % in pediatrics 
patients whereas 40-70% was observed among elderly and middle aged patients. 
Moreover, 2-3% isolates among middle aged and pediatric patients were resistant 
against imipenim while no resistance against imipenim was seen against elderly 
patients. Percent resistance against norfloxacin was quite high (74%) among pediatric 
patients compare to middle aged and elderly patients (55%). Rate of resistance against 
gentamycin was higher (75%) among pediatric patients than elderly and middle aged 
patients (50 %). Moreover, almost all of the isolates included in this study were found 
resistant to four or more antibiotics as shown in table 3.4. 
A total of 42% isolates were found to produce ESBL detected by the double 
disc diffusion test (Figure 3.1). Table 3.3 shows the frequency of ESBL producers for 
different UTI pathogens. Among the five most frequent UTI pathogens, E. coli (34.42 
%) and Klebsiella spp. (27.3 %) were most prevalent ESBL producers. Other isolates 
were also ESBL producers but their numbers were insignificant as shown in table 3.3. 
Statistical analysis revealed that the data obtained was obeying the normality 
as well as principle of homogeneity throughout; p-values were also calculated as 
indicated in Table 3.3. 
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Figure 3.1 ESBL detection by double disc synergy test. A: Ceftazidime (30^g), B: 
Cefixime (30(ig), C: Cephotaxime (30^g), D: Ceftriaxone (30fig) and E: Amoxyclav 
(20/10 Mg). 
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Table 3.4. Resistance patterns of various uropathogens. 
TT ^u No. of 
Uropathogens p^^^^^^ Resistance Patterns 
E.coli. 1 Cep', Cep^ Cep\ Cep*, Aran, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli, 
2 Cep', Cep^ Cep^ Cep'', Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli, Co and 
C. 
3 Cep', Cep^ Cep^ Cep\ Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli and C. 
4 Cep^, Cep', Cep"*, Mon, Qun, Lin. 
5 Cep\ Mon, Mac,Pen, Qun. 
6 Cep, Mac, Lin, Pen, Amn. 
7 Cep', Cep', Amn, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli.and Co. 
8 Cep', Cep', Amn, Pen, Qun, Fqn, Mac, Lin, Mon and Co. 
9 Cep', Cep^, Cep', Cep\ Mon, Pen, Mac, Lin, T, Nf, Bli. 
10 Cep', T, Nf, Co, C, Amn, Pen, Mon, Qun,, Mac, Lin. 
11 Cep', Nf, Bli, Co, Amn, Mon, Pen, Qun, Fqn, Mac, Lin. 
12 Cep', T, Nf, Co, Amn, Pen, Mac, Lin. 
13 Cep', Cep2, Cep', Cep^, Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli, Co. 
14 Cep',Cep^Cep', Cep*, Amn, Mon, Pen, Qun, Fqn, Lin, Nf, andC. 
15 Cep', Cep\ Cep', Cep*, Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli and Co. 
16 Cep', Cep^, Cep*, Qun, Mac, Lin, and Nf 
17 Cep', Cep^ Cep', Cep*, Amn, Mon, Pen, Qun, Mac, Lin, T, Bli, Co and C. 
18 Cep', Pen, Mac, Lin, T, Nf, Bli, Co and C. 
Mac, Lin, and Nf 
19 Cep', Cep*, Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf, Bli, Co and C. 
20 Cep^ Cep4, Qun, Bli, Nf, T, and Co. 
21 Cep', Cep^ Amn, Pen, Qun, Fqn, Mac, Lin, T, and Bli. 
22 Cep', Cep'' Pen, Qun, Fqn, Mac, Lin, T, Bli.and Co. 
23 Cep', Cep^ , Cep', Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Bli and Co. 
24 Cep*. Mon, Qun and Nf 
Klebsiella 
spp 
S. aureus. 
1 Cep', Cep^ Cep3 , Cep*, Amn, Mon, Pen, Qun, Fqn, Lin, Bli, T, Nf and C. 
2 Cep^, Cep*, Mon, Pen, Qun, Mac and Lin. 
3 Cep', Cep^ , Amn^MQ{i, Pen, Qun, Mac, Lin, T and Nf 
4 Cep', Pen, Fqn, Lin, Mac, T and Co. 
5 Pen, Nf, Mac and Lin. 
6 Cep', Cep*, Amn, Mon, Pen, Qun, Fqn, Mac, Lin, T, Nf and Co. 
7 Cep', Pen, Mac, Lin, TandC. 
8 Resistant to all the groups. 
1 Mon, Cep', Amp, Qun, fqn,Mac,and Co. 
2 Cep^ Cep', Pen, Qun, Fqn, Bli, C, T, Mon. 
3 Cep', Mon, Qun. 
4 Cep', Cep^ Cep* ,Pen, Fqn, Amn, Mac, Lin, Bli, C, T, Nf, and Co . 
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3.4. Discussion 
This study shows the distribution and antibiotic susceptibility pattern of 
microbial species isolated from patients with community acquired UTIs in J.N.M.CH, 
Aligarh. These organisms cause a variety of infections including UTIs [Schaeffer et 
al., 2002]. In this study urinary samples of children were also included. A majority of 
pathogens were isolated from adult patients (51.04 %), principally women (66.66 %). 
It has been extensively reported that adult women have a higher prevalence of UTI 
than men, principally owing to anatomic and physical factors [Biswas et al., 2006 and 
CLSI, 2000]. 
Antibiotic resistance is a major clinical problem in treating infections caused 
by these microorganisms. The resistance to the antimicrobials has increased over the 
years. Resistance rates vary from country to country [CLSI, 2001]. Overall, isolates 
from Latin American countries show the lowest susceptibility rates to all antimicrobial 
agents followed by Asian-Pacific isolates and European strains. Strains from Canada 
exhibit the best global susceptibility testing results. (SENTRY Antimicrobial 
Surveillance Program, SASP) [CLSI, 2001]. In our study, it accounted for 
approximately 61% of all clinically significant urinary isolates and 63% of all 
Enterobacteriaceae. This is consistent with the findings of previous studies in which 
E.coli was the predominant pathogen isolated from patients with community acquired 
UTIs [Gupta et al., 2002, and Meharwal et al., 2002]. However, Klebsiella spp. are 
rarely encountered in cases of community-acquired UTI [Biswas et al., 2006, Gupta et 
al., 2002, and Khan et al., 2004]. In the present study 22% of Klebsiella isolates were 
found to be present among all uropathogens studied. These isolates shows resistance 
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against first generation cephalosporin, cephalothin, aminoglycosides, macrolides and 
lincosamides which is consistent with the previous data of other community- based 
studies [Gales et al., 2001]. 
Our E. coli and Klebsiella isolates are equally resistant to ampicillin (76% and 
75% respectively) while for Co-trimoxazole, E. coli is more resistant (75%) than 
Klebsiella (53%) in this region. Indian isolates showed higher resistance against 
ampicillin and co-trimoxazole than the isolates from USA (39.1% and 18.6 % 
respectively) [Philippon et al.,1996 ] and Europe (29.8% and 14.1% respectively) 
[Kunin et al., 1994]. On the other hand, rate of resistance against these antibiotics in 
countries like Senegal (77% and 55%), Spain, (65% and 33%), Taiwan (80% and 
56%), and Israel (66% and 26%) is comparable with Indian isolates [Dimitrov et al., 
2003, Vromen et al., 1999, Kahlmeter et al., 2003, and Dromigny et al., 2002]. Our 
findings with regard to the overall high resistance of urinary E. coli strains to 
antibiotics such as Co-trimoxazole (76%), ampicillin (75%), and any beta-lactams 
studied (55-85%) are in agreement with those of other recent studies [Anatoliotaki et 
al; 2007, Garcia et al; 2007, Karki et al; 2001, Prelog et al; 2008]. This shows the 
limited possibility of using these antibiotics in the empirical treatment of UTIs. 
In this study E. coli and Klebsiella isolates are highly resistant against 
nitrofurantoin (80% and 76% resistant respectively). Whereas, this drug exhibited low 
resistance rate in the major part of the world (0-5.4%), despite of it's being used for 
many years [Daza et al., 2001]. This is probably due to the fact that this antibiotic has 
been widely used in treating community-acquired UTIs over the past decade in this 
region (Lau et al., 2004, Colodner et al., 2001, and Honderlick et al., 2006). The 
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resistance rate of E. coli to extended spectrum cephalosporins ranges from 55% to 
85%, which is contrary to other community-acquired UTI studies in Europe, Israel and 
the US [Dromigny et al., 2002, Mudur et al., 2000]. Higher resistance rate to all 
antibiotics used in this study with the exception of imipenem and amikacin may be 
explained as uncontrolled consumption of these antibiotics during the past decade in 
our region (Lau et al., 2004, Colodner et al., 2001, and Honderlick et al., 2006). 
In the present study overall imipenem resistance was 12 % for Klebsiella spp., 
whereas, other isolates of uropathogens were found to be sensitive to imipenem. It is 
highly stable against 6-lactamase and has an unusual property of causing a post 
antibiotic effect on gram-negative bacteria [Svetlansky et al., 2001]. Due to its small 
molecular size it can over come the poor permeability of B-lactams for Pseudomonas 
by efficient penetration through the porin, OMP D [Hillier et al., 2002]. Extended 
spectrum cephalosporins showed remarkable rates of resistance against E. coli, 
Klebsiella spp, S. aureus, Acinetobacter spp, and Pseudomonas spp. All S. aureus 
isolates were susceptible to third generation cephalosporins i.e. cephotaxime and 
ceftriaxone. Whereas, among Pseudomonas spp. all isolates showed resistance to 
cefyodoxime and cefuroxime. All Acinetobacter isolates were susceptible to amikacin 
and fluoroquinolones. The reported resistance varies from 10 to 30% in Pseudomonas 
spp. and 3 to 10.3% m Acinetobacter spp. 
In this study, 42 out of 100 isolates of UTI pathogens (42%) were found to 
produce ESBL. High prevalence rate of ESBL producing strains have also been 
reported earlier in Klebsiella spp. [Farrel et al 2003,and Neu et al., 1992]. This is 
consistent with other drug resistance groups in India (48.3%) [Amin et al., 2005]. A 
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2iAA2 % of our E. coli isolates were ESBL producers, followed by 27.3% oiKlebsiella 
spp. It might be possible that the high level of multi-drug resistance was most 
probably due to production of extended spectrum beta lactamases in these isolates 
[Grover et al., 2006, Mathai et al., 2002, and Mohanty et al 2005]. More studies are 
required to know the exact magnitude of the problem in India. 
3.5. Conclusion 
It is quite alarming to note that almost all of the isolates included in this study 
were found resistant to four or more antibiotics. Antibiotic resistance is becoming a 
big problem for the public health which threatens the lives of hospitalized individuals 
as well as those with chronic conditions and adds considerably to health care cost 
Therefore, it is an important issue to be addressed by the policy makers to formulate a 
strict antibiotics prescription policy in our country. Moreover, this study concludes 
that E. coli and other isolates were more sensitive to imipenem and amikacin 
compared to the other antibiotics tested and therefore these may be the drugs of choice 
for the treatment of community-acquired UTIs in our region. 
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4.1. Introduction 
Urinary tract infection (UTI) is an extremely common condition requiring 
antimicrobial therapy [Sefton et al., 2000]. Increasing antimicrobial resistance among 
bacteria causing UTI is therefore of great concern. Patterns of increased antimicrobial 
usage are the main driving force in generating and maintaining resistant bacteria 
[WHOjGeneva, Switzerland, 2001]. Studies also show that, once evolved, resistance 
genes can spread through the world's bacterial populations irrespective of the pattern 
of antimicrobial use in an area [O'Brien et al., 2002]. Therefore, mechanisms other 
than selection pressure might exist for maintaining a resistant bacterial pool. 
Epidemiological studies to better manage infections such as UTIs genially 
involve surveys of isolates from a defined location or locations for the purpose of 
identifying common resistance profiles [Tumidge et al., 2002; Farrel et al., 2003; 
Kurutepe et al., 2005]. These studies attempt to survey resistance to clinically 
important antibiotics generally or focus on particular families of antibiotics and their 
corresponding genes that encode resistance to them. Such surveys can lead to 
treatment strategies that make use of antibiotics to which strains are likely to be 
sensitive and can be useful in the short term for the development of detection and 
management strategies [Gupta et al., 2001; Tumidge et al., 2007]. However, they do 
not usually take into account the genetic contexts in which resistance genes are found. 
Presently several methods of bacterial strain typing are used such as bacteriophage 
typing, serotyping, plasmid fingerprinting, ribotyping, PCR-based methods. Most of 
these techniques are not sensitive enough to distinguish different strains or affected by 
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physiological factors. Hence, the most recommended technique used for genotyping of 
the strains is PFGE [Swaminathan et al., 1993; Arbeit et al., 1995]. 
One group of elements that has been an increasing focus of study in the context of 
UTIs is integrons. In particular, integrons belonging to classes 1, 2, and 3 are most 
commonly associated with the spread of antibiotic resistance among pathogens 
[Marquez et al., 2008]. Integrons are a problem generally in managing the spread of 
resistance, they are especially common in UTIs [Blahna et al., 2006]. Surveys that 
examine the prevalence of various genetic elements in multidrug-resistant UTI-
causing strains invariably show a high correlation between the presence of a class 1 
integron and particular antimicrobial resistance profiles. Most notable among these are 
resistance to ampicillin (AMP) and streptomycin but especially trimethoprim and sul-
famethoxazole (SMX) [Blahna et al., 2006; Solberg et al., 2006; Smith et al., 2008]. In 
case of class I integrons, SMX resistance is normally derived from the sul 1 gene that 
is contained within a region downstream of the integron called the 3' conserved 
segment (3'-CS), and this region is present in the majority of class 1 integrons from 
clinical environments. Consequently, SMX resistance is a common feature of strains 
that carry class 1 integrons. In addition, the use of co-trimoxazole (SXT) to treat UTIs 
and many other community acquired infections is most probable reason why a variety 
of dfrA gene cassettes are found in class 1 integrons from UTI mediating organisms, 
thus leading to SXT resistance being very common [Grape et al., 2005; Solberg et al., 
2006]. The ongoing use of antibiotics is associated with more complex multi-
resistance patterns attributable to the influx of more resistance genes into clinical 
isolates [Yu et al., 2003]. 
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The class 1 integrons that carry drug resistance genes in clinical isolates have a 
relatively conserved structure. This structure commonly comprises two conserved 
DNA sequences—the 5'-CS and 3'-CS—separating a variable region where mobile 
gene cassettes are located [Stokes et al., 1989]. This arrangement (5'-CS-variable 
region-3'-CS) has been used as a PCR tool for the simple recovery of cassette arrays 
irrespective of knowledge of the many and varied cassettes that may be present 
[Le'vesque et al., 1995; Recchia et al., 1995]. As well as being able to recover and 
analyze cassettes from specific isolates, this method has also been used as a tool in 
broader epidemiological studies [Jones et al., 2003; Severino et al., 2004]. Among 
Enterobacteriaceae, prevalence of integrons varies and has been reported up to 59% 
[Jones et al., 1997; Martinez et al., 1998; Fluit et al., 1999; White et al., 2001; Lee et 
al., 2001; Schmitz et al., 2001; Leverstein et al., 2002]. There is, however, a paucity of 
data from community-acquired infections. In one such study from Netherlands 19% of 
E. coli had integron class 1 [Leverstein et al., 2002]. No such data were obtained from 
India although prevalence of co-trimoxazole resistance is high among E. coli. 
Multidrug-resistant Enterobacteriaceae (MRE) strains are being isolated at an 
increasing rate in hospital settings and are having a significant impact on clinical 
practice and overall treatment costs [Cross et al., 1983; Holmberget al., 1987; Cohen 
et al., 1992; Hobson et al., 1996; Leverstein et al., 2001]. This multi-resistance may be 
mediated by chromosomally located resistance determinants or mutations in a resident 
gene; however, it may also develop through the acquisition of resistance genes or an 
array of resistance genes by horizontal gene transfer. This latter phenomenon is 
currently thought to play an important role in developing multi-drug resistance in 
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Enterobacteriaceae [Rowe et al., 1996]. Plasmids and transposons are known to be 
involved in the transfer of resistance genes from one cell to another. These elements 
can hunt as a pack by interacting with each other in a variety of ways that enhance 
their collective ability to transfer resistance genes. Some of the plasmids which carry 
multiple resistance genes also have transfer systems that enable them to transfer DNA 
between unrelated species (promiscuous or broad host range plasmids) [Hall et al., 
1997]. Several studies have investigated the prevalence of integrons in clinical isolates 
and have found them to be widespread [Sallen et al., 1995; Gonzalez et al., 1998; 
Martinez et al., 1998]. However, the kinds of gene cassettes inserted into the integrons 
were not identified, except in the work of Sallen et al., [Sallen et al., 1995]. 
The incidence of nosocomial infection caused by members of the family 
Enterobacteriaceae that produce ESBLs and other enzymes capable of hydrolyzing 
cefotaxime, ceftriaxone, ceftazidime and aztreonam is increasing worldwide [Tenover 
et al., 1999]. Extended spectrum beta-lactamases (ESBL)-producing organisms pose a 
therapeutic challenge as they do not only mediate resistance to oxyimino-
cephalosporins, but as they are also frequently resistant to other kinds of antimicrobial 
drugs, including aminoglycosides, fluoroquinolones, tetracycline, gentamicin and 
trimethoprim-sulphamethoxazole [Martinez et al., 1998; Paterson et al., 2000; 
Gniadkowski et al., 2001; Winokur et al., 2001; Edelstein et a!., 2003; Eckert et al., 
2004; Rodriguez et al., 2004]. Most ESBLs are mutants of TEM and SHV enzymes, 
but CTX-M enzymes are increasingly important as a major source of resistance. Over 
40 CTX-M beta-lactamases have been described [Woodford et al., 2004]. CTX-M 
type ESBLs are mainly found in E. coli strains. CTX-M producers are most frequently 
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found in urinary tract infections [Johnson et al., 2002; Bonnet et al., 2004; Pitout et al., 
2005; Lavigne et al., 2006]. Most known CTX-M enzymes are CTX-M-1 and CTX-
M-15 [Bonnet et al., 2004; Canton et al., 2006]. The present study was aimed to 
investigate the prevalence of CTX-M type enzymes in community acquired E. coli 
isolates. PCR based methods have been proved extremely effective in detecting 
antimicrobial resistance genes of complex mechanisms found in Gram negative and 
Gram positive bacteria, including among others, those encoding P-lactam resistance in 
Enterobacteriaceae [Pfaller et al., 2001]. It has the advantage of being speedy, 
sensitive and specific [Mims et al., 1998; Schwarts et al., 2002] and can produce 
extremely large number of relevant genes [Eglinton et al., 1996]. 
4.2. Experimental overview 
Extended spectrum beta-lactamases producing E. coli isolates were selected for 
the screening of CTX-M B-lactamases by using PCR methods as discussed in section 
3.7.3. Integron screening was also performed. Integron positive isolates were 
sequenced. These ESBLs producing E. coli strains were typed by pulsed field gel 
electrophoresis technique described in section 4.1. Conjugation studies for marker 
transfer were also carried out on these strains by broth mating method as discussed in 
section 3.5. 
4.3. Results 
4.3.1. PFGE-analysis 
Of twenty two ESBLs producing E. coli isolates, eight strains were subjected to 
PFGE to investigate their clonality. Banding patterns and clusters were interpreted 
using the guidelines suggested by Tenover [Tenover et al., 1995]. These strains were 
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grouped in to different subtypes. The results are shown in table 4.1. Considering the 
criteria by Tenover [Tenover et al., 1995], we found that six isolates had 2-5 fragment 
differences and were grouped under different subtypes; designated as A, Al, A2, A3, 
A4, and A5. Because the restriction pattern was unique for the other two isolates, we 
could not include these isolates in any of the six subtypes, so they were classified into 
two separate PFGE type B and C. (Figure 4.1). 
4.3.2. Integron screening 
In total, seven isolates were evidenced for the class 1 integrons among the 
twenty two ESBLs producing E .coli isolates. The amplification products of class 1 
integrons varied in size between 0.9 and 2.3 kbp (Figure 4.2 A & B; Table 4.2). These 
integron harboring isolates were further screened for the presence of Intl and SuU 
genes, which are characteristic features of class! integrons. All the seven integrons 
were found to be positive for these genes.The amplification products of Intl and Sull 
genes were found to be 845 bp and 840 bp respectively (Figures 4.3 and 4.4 A & B). 
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Table 4.1. Genotyping of ESBL producing E. coli isolates. 
Strains PFGE types 
UE-61 A 
UE-90 Al 
UE-133 A2 
UE-112 A3 
UE-152 A4 
UE-170 
UE-64 
UE-128 
A5 
B 
C 
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483 
Fgure.4.1. PFGE profiles of ESBLs producing E. coli strains isolated from different 
uti patients. Lateral lane contains multi-mers of phage lambda DNA (48.5 kb) 
molecular mass markers. Sizes of lambda DNA molecular mass markers are indicated 
on the left of the panel. Different PFGE types and subtypes identified are indicated on 
the top of each lane. 
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Table 4.2. Association of integrons with multiple drug resistance in E .coli isolates. 
Isolates Integron Antibiogram Gene cassettes 
content 
UE-61 0.97kb lGC,2GC,3GC,4GC,Amn,Pen,Quin,Fquin,Ac aadAl 
UE-90 1.99kb lGC,2GC,3GC,4GC,Amn,Pen,Quin,Fquin,Nf,Ac, Co aadA5, dfrAl? 
UE-112 2.21 kb 1 GC,2GC,3GC,4GC,Amn,Co,C,Quin,Fquin,Nf,Ac aacA4, dfrA 1, CmlA 1 
UE-128 2.3Ikb 1GC,2GC,3GC, Pen,Quin,Fquin,Nf,Ac None 
UE-133 1.95kb 1 GC,2GC,3GC,4GC,G,Tb,Pen,Quin,Fquin,Ac, Co aadA5, dfrA17,dfrA7 
UE-I52 2.04kb lGC,2GC,3GC,4GC,Amn,Co,Quin,Fquin,Nf,Ac aadA5, dhfrAlV, dfrA? 
UE-170 0.90kb lGC,2GC,3GC,4GC,G,Ak,Co,Pen,Quin,Fquin,Nf,Ac aadA2, dhfrA12 
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10 
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1.5 
1.0 
0.5 
Figure 4.2 (A). PCR amplification of 5'-CS-3'-CS conserved sequences of integron. 
Lane M: 1 Kb DNA ladder, Lane P: Positive control, Lane 1-5: E. coli clinical isolates 
(UE-128, UE-133, UE-137, UE-112, UE-170) and Lane 6: Negative control. 
M P 1 2 3 
Kb 
10 
2.5 
1.5 
1.0 
0.5 
Figure 4.2 (B). PCR amplification of 5'-CS-3'-CS conserved sequences of integron. 
Lane M: 1 Kb DNA ladder. Lane P: Positive control. Lane 1-3: E. coli clinical isolates 
(UE-61, UE-90, UE-152) and Lane 4: Negative control. 
Chapls2r-4 
M P 1 4 5 
Kb 
1.5 
1.0 
0.5 
Kb 
0.845 
Figure 4.3 (A). Integron mapping by PCR arrplification of Intl gene. Lane M: 1 Kb 
DNA ladder, Lane P: Positive control, Lane 1-5: E. coli clinical isolates (UE-61, UE-
90, UE-112, UE-128, UE-133) and Lane 6: Negative control. 
M P 1 2 3 4 5 6 
Kb 
5.0 
2.0 
1.0 
Kb 
0.845 
Figure 4.3 (B). Integron mapping by PCR amplification of Intl gene. Lane M: 1 Kb 
DNA ladder, Lane P: Positive control, Lane 1-5: E. coli clinical isolates (UE-137, UE-
152, UE-170, UE-144, UE-103) and Lane 6: Negative control. 
..^.:^' 
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Kb 
5.0 
2.0 
1.0 
Kb 
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Figure 4.4 (A). Integral mapping by PCR amplification of Sull gene. Lane M; 1 Kb 
DNA ladder, Lane P: Positive control, Lane 1-5: E. coli clinical isolates (UE-61, UE-
90, UE-112, UE-128, UE-133) and Lane 6: Negative control. 
M 1 2 3 
Kb 
5.0 
1.0 
2.0 
Figure 4.4 (B). Integron mapping by PCR amplification of Sull gene. Lane M: 1 Kb 
DNA ladder. Lane 1-2: E. coli clinical isolates (UE-152, UE-170) and Lane 3: 
Ne^tive control. 
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4.3.3. Integron sequence analysis 
Purified PCR products were subjected to DNA sequencing by using the 
commercial facility at Macrogen, South Korea, to look for the resistance gene 
cassettes present in these strains. Sequencing data obtained in an electronic format 
were compared to the GenBank database of the National Centre for Biotechnology 
Information BLAST network [Altschul et al., 1990]. DNA sequencing of class 1 
integrons showed the presence of one to three gene cassettes and the combinations of 
these (Table 4.2). Most of the gene cassettes found within the variable region of class 
1 integrons in our E. coli isolates corresponded to different variants of dfrA and aadA 
genes. These genes are associated with trimethoprim and streptomycin resistance 
respectively, and aadA5-dfrA17-dfrA7 was the combination of gene most prevalent in 
our study. One PCR product of about the same size, derived from E. coli isolate UE-
112, contained a aacA4-dfrAl-CmlAl array. CmlA cassette encodes chloramphenicol 
transporter known as chloramphenicol resistance gene. A 2 kbp amplicon amplified 
from E. coli UE-90 genomic DNA was found to contain aadA5, dhfrl7 gene cassettes. 
The aadAl gene cassette encoding aminoglycoside 3'(9)-0-adenyltransferase 
associated with streptomycin and spectinomycin resistance was found only in one 
amplicon of 0.97 kbp while other amplicon of same size was found to have aadA2 and 
dhfrl2 gene cassettes which encode resistance to both aminoglycosides and 
trimethoprim-sulfamethoxazole respectively. No such gene cassettes were found in 2.3 
kbp amplicon. 
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4.3.4. Screening of ESBLs coding genes 
Of 65 E. coli isolates, only 22 E. coli strains had a phenotype consistent with 
production of an ESBL. These 22 E. coli isolates were screened for the presence of 
cefotaxime hydrolyzing 6-lactamases (CTX-M) on both plasmid as well as genomic 
DNA by PCR using universal primers. Only 3 strains exclusively demonstrated alleles 
encoding CTX-M enzymes belonging to phylogenetic group 1 (CTX-M-1-related 
enzymes). One strain was found to contain CTX-M gene both on plasmid as well as 
genomic DNA while other two were on Chromosomal DNA only. No alleles encoding 
for CTX-M-2-related enzymes or CTX-M-9- related enzymes were found. The size of 
PCR product was found to be 604 bp (Figure 4.5). These CTX-M positive isolates 
were further screened for the presence of TEM and SHV beta-lactamases by PCR. Out 
of three CTX-M positive isolates two were found positive for TEM, while all the three 
were found negative for SHV (Figure 4.7). The PCR amplicons of CTX-M gene were 
subjected to digestion with Hinfl and it was found that the three fragments of 304, 200 
and 100 bp were observed in all the 3 CTX-M positive isolates (Figure 4.6). All the 
three purified PCR products of CTX-M gene and two of TEM, were sequenced by 
using commercial facility at Chromous Biotech, New Delhi, India. Sequencing data 
obtained in an electronic format were compared to the GenBank database of the 
National Centre for Biotechnology Information BLAST network [Altschul et al., 
1990]. The nucleotide sequence analysis showed that all the three CTX-M gene 
amplicons belong to blacrx-M-is gene while that of TEM were bla TEM-I-
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Kb 
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Figure 4.5. PCR amplification of CTX-M gene. Lane M: 1 Kb DNA ladder, Lane P: 
Positive control. Lane 1-4: E. coli clinical isolates (UE-90, UE-112, UE-112P, UE-
152) and Lane 5: Negative control. 
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M 1 2 3 4 5 6 7 
Figure 4.6. Hinfl restriction fragment analysis of amplified fi^agment of CTX-M gene 
in different strains. Lane M: 1 Kb DNA ladder, Lane 1 and 6: Negative control 
(undigested), Lane 2A: E. coli clinical isolates (UE-90, UE-112, and UE-1I2P) and 
Lane 5: pBR322 as positive control. 
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Kb 
10 
2.5 
1.5 
1.03 
0.5 
Kb 
1.09 
Figure 4.7. PCR amplification of TEM-1 gene. Lane M: 1 Kb DNA ladder, Lane 1-3: 
E. coli clinical isolates (UE-90, UE-112, UE-112P) and Lane 4: Negative control. 
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Table 4.3. Number of resistance markers and transfer characteristics of piasmid carrying 
uropathogenic E. coli isolates. 
Isolate 
UE-59 
UE-61 
UE-64 
UE-67 
UE-68 
UE-70 
UE-92 
UE-93 
UE-95 
UE-96 
UE-98 
UE-102 
UE-103 
UE-112 
UE-128 
UE-133 
UE-137 
UE-144 
Micro-
organism 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
E.coli 
No. of 
Resistance 
markers 
25 
23 
07 
11 
13 
08 
24 
15 
08 
11 
24 
13 
23 
23 
01 
08 
02 
14 
No. of 
Transferred 
Resistance 
markers 
13 
09 
04 
10 
07 
05 
07 
13 
02 
05 
18 
09 
15 
04 
01 
01 
01 
12 
No.ofEJ-53 
receiving T 
resistance 
5.04x10^ 
2.6x10^ 
1.12x10^ 
2.6x10^ 
5.04x10' 
1.12x10^ 
3.24x10^ 
3.24x10^ 
2.6x10^ 
3.24x10^ 
2.6x10^ 
3.24x10^ 
1.12x10^ 
1.12x10^ 
5.04x10'' 
4.03x10^ 
5.04x10' 
1.12x10'' 
Total no. of 
EJ-53 
1.02x10^ 
2.12x10^ 
4.04x10' 
2.12x10* 
2.12x10* 
2.12x10* 
1.02x10^ 
4.04x10' 
2.12x10* 
2.12x10* 
4.04x10' 
4.04x10' 
4.04x10' 
2.12x10* 
1.02x10^ 
4.04x10' 
4.04x10' 
2.12x10* 
Transfer 
frequency 
(%) 
0.049 
0.012 
0.0027 
0.012 
0.237 
0.00052 
3.17x10"^ 
0.80x10"* 
0.012 
1.52x10"^  
0.064 
0.80x10"^ 
0.0027 
0.00052 
0.049 
0.997x10"^ 
1.24 
0.52x10"' 
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4.3.5. Horizontal gene transfer 
Eighteen of the twenty-two E. coli cultures transferred their drug resistance 
through conjugation to EJ-53 as recipient susceptible strain. Table 4.2 illustrates the 
characteristics of the 18 £. coli strains which transferred drug resistance and the 
frequency of transfer of resistance to EJ-53. Transfer frequency varied between 3.17 
X10'^  and 5.2x10". All of the 18 strains of £. coli which showed transfer of resistance 
markers to the susceptible strain having at least 1-25 antimicrobial resistant markers 
(Table 4.3). In all the cases, 01-17 resistance markers were found to be transferred to 
EJ-53 strain. Plasmid DNAs were isolated from both donor as well as trans-conjugants 
and electrophoresed on 0.7 % agarose gel (Figure 4.8 A and B). Sizes of plasmids 
were calculated by quantity one software and were found to be 18-19 kb. 
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3M 3 4 
Kb 
10 
6 
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1.03 
Figure 4.8. (A). Agarose gel electrophoresis of plasmid DNA isolated from donor and 
transconjugants of clinical isolates ofE. coli. Lane M: 1 Kb DNA ladda, Lane 1-4: 
donor and transconjugants( UE-128, UET-128, UE-133, UET-133). 
M l 2 3 4 5 6 
Kb 
10 
5 
Kb 
18 
Figure 4.8 (B) Agarose gel electrophoresis of plasmid DNA isolated from donor and 
transconjugants of clinical isolates of £. coli. Lane M: 1 Kb DNA ladder, Lane 1-6: 
donor and transconjugants( UE-61, UET-61, UE-67, UET-67,UE-70, UET-70). 
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4.4. Discussion 
The present study was performed on the isolates from community-acquired 
urinary tract infections. Resistance to more than three antibiotics was common among 
these isolates. It shows that integrons are widespread among these community-
acquired E. coli UTI in one part of the India and play a significant role in the 
prevailing multidrug resistance situation. Integron prevalence among E. coli in low-
income countries seems to be similar to have in many European countries. 
Escherichia coli is the most common uropathogen and accounts for more than 
80% of UTI cases. Twenty-two of all the resistant E. coli isolates that were ESBL-
producers were selected for this study. Genotyping of these isolates could reveal 
whether isolates are clonally related, i.e. have common origins in suspected 
nosocomial/community outbreaks or possible cross-transmission events [Adamsson et 
al., 2002]. PFGE has been used in many studies to show the international spread of 
Methicillin-Resistant Staphylococcus aureus (MRSA), and the criteria used for micro 
epidemiological analyses have frequently been employed [Cookson et al., 2007]. 
Tenover criteria [Tenover et al., 1995] are simple and helpful for genotyping a group 
of bacteria based on PFGE, which are closely related. The increased development of 
resistant strains causing severe nosocomial or community infections has been a major 
driving force for the development of new antibiotics but more importantly to find a 
way of preventing the spread. Epidemiological studies regarding dissemination 
pathways of potential pathogens in the community and hospital wards are of great 
concern. 
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Integrons play an important role in the antimicrobial resistance of clinical 
Escherichia coli strains because they are able to capture, integrate and express gene 
cassettes encoding proteins associated with antimicrobial resistance. The presence of 
integrons in clinical multi-resistant E. coli isolates recovered from the community as 
well as hospital environment is frequently reported [Schmitz et al., 2001; Hall et al., 
2002; Mathai et al., 2004; Fonseca et al., 2005; Solberg et al., 2006; Machado et al., 
2007]. Our data revealed the prevalence of integrons in uropathogenic E. coli, 
whereas earlier studies in Asia and Europe also supports our findings [Chang et al., 
1997; Yu et al., 2003; Mathai et al., 2004; Yu et al., 2004; Grape et al., 2005; Solberg 
et al., 2006). Other reports have shown the prevalence of class 1 integrons in gram-
negative clinical isolates to be 43% in Western and Central Europe [Martinez et al., 
1998], >50% in the Netherlands [Jones et al., 1997] and 59% in France [Sallen et al., 
1995]. These results, together with those obtained in the present study; indicate that 
the class 1 integrons are widespread in clinical isolates. This study has undertaken to 
examine the role of integrons in prevailing antimicrobial resistance situation in India, 
showed that integrons are widespread and that they play a major role in producing 
MDR among E. coli isolates. The prevalence of integrons (33%) in northern Indian 
isolates tested was similar to that found in the study of Mathai et al., from south India 
[Mathai et al., 2004]. As previously noted, integrons of class 1 were more prevalent 
than integrons of class 2 [Conway et al., 2007; Foxman et al., 2000]. E. coli with 
integrons were significantly more likely to exhibit MDR and resistance to 
cephalosporins, gentamicin, chloramphenicol, ampicillin, nalidixic acid and 
amoxyclav. The screening for integrons has been performed using three different pairs 
-103-
Chaptizr-4-
of primer. One primer pair gives products of the entire class 1 integron including the 
different gene cassettes. This is very useful for estimation of size and gene cassette 
content of the class 1 integron. The second pair of primer used in this study consisted 
therefore of two primers specific for the integrase class 1 gene only. Since this gene is 
essential for the function of the integron, all isolates positive for the integrase class 1 
gene can hence also be considered positive for integrons of class 1. The third primer 
pair used was specific for SuU gene which is located at 3'-CS. Most of the gene 
cassettes found within the variable region of class 1 integrons in our E. coli isolates 
corresponded to different variants of dfrA and aadA genes. These genes are associated 
with trimethoprim and streptomycin resistance, respectively, and dfrA 17- aadA5-
dfi-A7 was in combination most frequently detected not only in our study but also in E. 
coli isolates recovered from healthy and sick humans, animals and foods in other 
studies [Eisenach et al., 1995; AAPC, 1999; Beetz et al., 2002; Blahna et al., 2006; 
CLSl., 2006; Anatoliotaki et al., 2007; Conway et al., 2007]. The reason for the wide 
distribution of some successful integrons with a specific arrangement is not known, 
although the possible inclusion of these integrons in transposons and/or plasmids 
could explain their wide dissemination in different environments. 
The prevalence of class 1 integrons (33%) is in agreement with the prevalence 
found in similar Indian (36% [Mathai et al., 2004]), Korean (55% [Yu et al., 2003]), 
and Australian (46% [White et al., 2001]) studies. A Swedish study on urinary E. coli 
isolates in a general population showed the higher rate of prevalence of class 1 
integrons [Grape et al., 2005]. 
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Usually sulfamethoxazole resistance is encoded by the Sul genes. We found that 
seven E. coli strains possessed Sull genes, and all showed sulfamethoxazole resistance 
phenotype. Contrary to our data earlier studies showed that the SuI2 gene was more 
predominant in E. coli strains isolated in UTI episodes [Kerm et al., 2002; Blahna et 
al., 2006]. In our study, SXT treatment was associated with the occurrence of Sul 
genes and with increased phenotypic resistance to SXT. The association between 
resistance to nalidixic acid and integrons is interesting since resistance to quinolones is 
primarily chromosomal and we have all the seven integrons located on E. coli 
chromosomal DNA. 
ESBL production is the major emerging mechanism of resistance to 
expanded spectrum cephalosporins and mono-bactams among Enterobacteriaceae and 
is a matter of major concern in the field of microbial drug resistance. In the European 
scenario, where the TEM- and SHV-type ESBLs were first detected [Knoth et al., 
1983; Sougakoff et al., 1988] and are widespread [Perilli et al.,2002; Morris et al., 
2003; De Champs et al., 2004; Paterson et al., 2005; Rodriguez et al., 2006], recent 
reports have shown a rapid and alarming dissemination of Enterobacteriaceae, 
producing ESBLs of the CTX-M type in some countries, with notable changes in the 
epidemiologies of these resistance determinants [Eckert et al., 2004; Woodford et al., 
2004; Livermore et al., 2005]. This work has provided insights of molecular 
epidemiology of emerging problem in India. Unlike in other countries (e.g., Spain, 
France), where members of multiple CTX-M lineages have been reported [Eckert et 
al., 2004; Valverde et al., 2004], a virtually absolute prevalence of the members of the 
CTX-M-1 lineage was observed in this study. 
-105 
ChQpt^r-4 
Our findings were contrary to an Indian study, in which a variant of the bla-cTx-M-3 
enzyme, designated as bla-cxx-M-is, was reported from 6 unrelated members of 
Enterobacteriaceae isolated between April and May 2000 [Sekar et al., 2006]. The 
authors reported that 44.4% of E. coli and 35.29% of K. pneumoniae strains were 
found to be positive for bla-cix-M gene. However, our results were consistent with the 
findings of Shahid et al., 2006, with lower frequency of E. coli isolates being found to 
be CTX-M group-1 positive by PCR in the northern Indian isolates. 
The results of the conjugation experiments were supportive of the hypothesis that 
horizontal transfer of some of the resistance markers took place in vivo. [Maurine et 
al., 2002]. It was interesting to note that the complete resistance patterns (except for 
known chromosomally located resistance determinants), were transferred in their 
entirety in most of the conjugation experiments, suggesting a very efficient 
mechanism of transferring packages of resistance genes. 
4.5. Conclusion 
This study concludes that the integrons are one of the means of antibiotic resistant 
marker transfer among members oi Enterobacteriaceae. However, their prevalence in 
different areas appeared to be highly variable, which could reflect the scenario of a 
relatively early stage of dissemination of these resistance determinants in the 
community setting. Continuing surveillance will be necessary to monitor the evolution 
of extended spectrum beta-lactamases and to verify whether the CTX-M type ESBLs 
will eventually prevail over the TEM- and SHV-type ESBLs, which are still 
widespread, especially in some areas. It will also be interesting to investigate if these 
epidemiological differences could reflect differences in regional antimicrobial 
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policies. Our findings unveil the increasing role of the bla-crx-M 6-lactamases in 
antibiotic resistance and emphasize on the significance of appropriate empirical 
treatment for infections caused by coliforms, especially in urinary tract infection 
patients. In conclusion, the data presented here illustrates the complexity and extent of 
the spread of ESBL-producing Enterobacteriaceae among the tertiary care hospital 
patients. This study also shows that the horizontal gene transfer of antimicrobial 
resistance genes can occur very efficiently and at a high rate among 
Enterobacteraceae in a community setting. The phenotypic resistance patterns in the 
investigated isolates do not directly reflect the antibiotic usage for urinary tract 
infections in geographic location and at the time of isolation. Part of the explanation is 
the possibility of co-selection, because of the conjugative plasmids contains multiple 
resistance determinants. Another part of the explanation may be the overall 
antimicrobial agents used in the community. All antimicrobial agents used may 
provide a selection pressure on other enteric bacteria, which may transfer resistance 
genes to Escherichiae coli. Further studies are needed, however, to determine whether 
antibiotic policies or other measures can halt or lower the level of horizontal transfer 
that occurs in a hospital or community setting. 
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flppizndix 
Appendix 
(A) Composition of EET buffer for PFGE 
lOOmMEDTA 
lOmMEGTA 
10mMTris-HcI,pH8.0 
(B) Composition of proteolysis buffer for PFGE 
EET buffer 
20% SDS 
Proteinase K (500 |ig/ml) 
(C) Composition of wash buffer witli or without PIMSF for PFGE 
10mMTris-Hcl,pH7.5 
10 mm EDTA 
1 mM PMSF 
(D) Composition of equilibration buffer for PFGE 
lOX restriction enzyme assay buffer 
Autoclaved double distilled water 
(E) Composition of 10X TBE buffer 
45 mM Tris 
45 mM Borate 
1.0 mM EDTA, pH 8.3 
- 1 3 1 -
fjppizndix 
(?) Composition of different growth media 
The composition of brain heart infusion broth is as follows: 
Component gms/1 
Beef infusion from 250.0 
Calf brain infusion from 200.0 
Proteose peptone 10.0 
Sodium chloride 5.0 
Disodium phosphate 2.5 
Dextrose 2.0 
Dissolve 37gms in 1000 ml water, pH 7.4± 0.2 at 25°C. 
The composition of tryptone soya broth is as follows: 
Component gms/1 
Casein enzymic hydrolysate 17.00 
Papaic digest of soyabean meal 3.00 
Sodium chloride 5.00 
Dopotassium phosphate 2.50 
Dextrose 2.50 
Dissolve 30gms in 1000 ml water, pH 7.3± 0.2 at 25°C. 
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